[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 111
1. Lall DG, Karanjia ND, Giddings AE: Regional pancreatectomy and transverse colectomy with mesenteric vascular reconstruction for inflammatory pseudotumour of the head of pancreas and mesenteric root. HPB (Oxford); 2002;4(4):179-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional pancreatectomy and transverse colectomy with mesenteric vascular reconstruction for inflammatory pseudotumour of the head of pancreas and mesenteric root.
  • BACKGROUND: Inflammatory myofibroblastic pseudotumour is a rare pancreatic lesion.
  • CASE OUTLINE: A 32-year-old woman with such a tumour was treated by a radical operation comprising proximal pancreatic-duodenectomy (Whipple Procedure) and transverse colectomy with resection and reconstruction of the superior mesenteric artery and vein.
  • DISCUSSION: The importance of aggressive surgical clearance rather than chemotherapy is highlighted in the management of patients with these unusual tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1992 Dec;79(12):1357-60 [1486440.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):102-10 [9606802.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1247-51 [7475715.001]
  • (PMID = 18332951.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020548
  •  go-up   go-down


2. Distler M, Rückert F, Dittert DD, Stroszczynski C, Dobrowolski F, Kersting S, Grützmann R: Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol; 2009;7:22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
  • BACKGROUND: Acinar cell carcinoma (ACC) represents only 1-2% of pancreatic cancers and is a very rare malignancy.
  • At the time of diagnosis only 50% of the tumors appear to be resectable.
  • Reliable data for an effective adjuvant or neoadjuvant treatment are not available.
  • MRI-imaging showed a tumor within the head of the pancreas concomitant with Serum-Lipase and CA19-9.
  • Laparotomy presented an locally advanced tumor with venous infiltration that was consequently deemed unresectable.
  • Chemotherapy was well tolerated, and no severe complications were observed.
  • Twelve months later, the patient was in stable condition, and CT-scanning showed an obvious reduction in the size of the tumor.
  • Histopathological examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to be negative.
  • Therefore, neoadjuvant chemotherapy could be an option to reduce a primarily unresectable ACC to a point where curative resection can be achieved.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / surgery. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • (PMID = 19239719.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2657786
  •  go-up   go-down


3. Kuramitsu T, Naganuma T, Zeniya A, Otani S, Yoshida T, Ito S, Matsudaira N, Kano M, Komatsu M: Poorly vascularized malignant insulinoma displaced the pancreatic ducts around the mass on endoscopic retrograde cholangiopancreatography. Intern Med; 2001 Jan;40(1):28-31
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly vascularized malignant insulinoma displaced the pancreatic ducts around the mass on endoscopic retrograde cholangiopancreatography.
  • Abdominal ultrasonography (US) and endoscopic US revealed an isoechoic mass measuring 25 mm in the head of the pancreas.
  • Endoscopic retrograde cholangiopancreatography (ERCP) revealed that the main pancreatic duct and its branches were displaced around the mass in the head of the pancreas.
  • On arteriography, a poorly vascularized tumor was observed.
  • Dynamic contrast-enhanced computed tomography (CT) showed a low-attenuation mass in the head of the pancreas.
  • Microscopically, the diagnosis was malignant insulinoma.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Female. Glucose / therapeutic use. Humans. Hyperinsulinism / etiology. Hypoglycemia / drug therapy. Hypoglycemia / etiology. Insulin / analysis. Magnetic Resonance Imaging. Mesenteric Arteries / radiography. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Unconsciousness / drug therapy. Unconsciousness / etiology

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201365.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Insulin; IY9XDZ35W2 / Glucose
  •  go-up   go-down


Advertisement
4. Choi SH, Hwang HK, Kang CM, Lee WJ: Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas. JOP; 2010;11(6):638-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas.
  • CONTEXT: Mucinous cystic tumors occur almost exclusively in middle-aged women and in the body or tail of the pancreas.
  • Mucinous cystadenocarcinoma, a malignant sub-type of mucinous cystic tumors, in the head of the pancreas and in a middle-aged man is extraordinary, and the prognosis and proper management of mucinous cystadenocarcinoma has not been well documented.
  • CASE REPORT: A 52-year-old male patient with a mucinous cystadenocarcinoma approximately 5.5 cm in size in the head of the pancreas underwent a total pancreaticoduodenectomy and segmental resection of the superior mesenteric vein-portal vein confluence with an autologous splenic vein graft due to tumor invasion.
  • His postoperative course was uneventful and he received adjuvant chemotherapy.
  • CONCLUSION: Mucinous cystadenocarcinoma in the head of the pancreas in a middle-aged man is an extremely rare case.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Mesenteric Veins / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Portal Vein / surgery. Splenic Vein / transplantation
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21068503.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Saif MW: Pancreatoblastoma. JOP; 2007;8(1):55-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatoblastoma (PB), or infantile pancreatic carcinoma, is an extremely rare pancreatic tumor in childhood, comprising 0.5% of pancreatic non-endocrine tumors.
  • Mechanical obstruction of the upper duodenum and gastric outlet by tumor in the head of the pancreas may be associated with vomiting, jaundice and gastrointestinal bleeding.
  • The majority of these tumors arise in the head of the pancreas.
  • Ultrasound and CT scan may be useful but preoperative diagnosis is often quite difficult.
  • The treatment of choice is complete resection, that may often be curative.
  • The role of adjuvant chemotherapy or radiotherapy is still under discussion due to small number of patients treated as yet.
  • Chemotherapy regimens consisting of cyclophosphamide, etoposide, doxorubicin, and cisplatin have been used in neoadjuvant setting with anecdotal benefit.
  • Prognosis of this rare tumor is good, when resected completely.
  • On the whole, PB is regarded to be a curable tumor; hence the clinical diagnosis should be made early.
  • Awareness of this rare tumor of pancreas is essential for early detection and proper management.
  • The author review the clinical presentation, etiology, diagnosis, treatment and prognosis of PB in this presentation.
  • [MeSH-major] Carcinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Pancreas / pathology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228135.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Bachireddy P, Tseng D, Horoschak M, Chang DT, Koong AC, Kapp DS, Tran PT: Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiat Oncol; 2010;5:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.
  • PURPOSE: To analyze the outcomes of patients from a single institution treated with surgery and orthovoltage intraoperative radiotherapy (IORT) for pancreatic adenocarcinoma.
  • Most tumors were located in the head of the pancreas (83%) and sites irradiated included: tumor bed (57%), vessels (26%), both the tumor bed/vessels (13%) and other (4%).
  • The majority of patients (83%) had IORT at the time of their definitive surgery.
  • Additional mean clinical characteristics include: age 64 (range 41-81); tumor size 4 cm (range 1.4-11); and IORT dose 1106 cGy (range 600-1500).
  • Post-operative external beam radiation (EBRT) or chemotherapy was given to 65% and 76% of the assessable patients, respectively.
  • Outcomes measured were infield control (IFC), loco-regional control (LRC), distant metastasis free survival (DMFS), overall survival (OS) and treatment-related complications.
  • Our cohort had three grade 3-5 complications associated with treatment (surgery and IORT).
  • CONCLUSIONS: Orthovoltage IORT following tumor reductive surgery is reasonably well tolerated and seems to confer in-field control in carefully selected patients.
  • However, distant metastases remain the major problem for patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42 [20207498.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):16-21 [12576918.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Oct;12(4):899-924 [14989123.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1957-65 [6490425.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):255-9 [3949576.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):195-200 [2081924.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Cancer. 1997;76(11):1474-9 [9400944.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):227-34 [9880768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Oncol. 2006;45(2):124-35 [16546857.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):335-46 [17674962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11 [17560736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1094-9 [18313525.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):318-25 [18199514.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Radiother Oncol. 2009 Apr;91(1):54-9 [18762346.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2855-62 [19398572.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2116-22 [19437078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • (PMID = 21059255.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987939
  •  go-up   go-down


7. Nakazawa T, Naitoh I, Ando T, Hayashi K, Okumura F, Miyabe K, Yoshida M, Ohara H, Joh T: A case of advanced-stage sclerosing cholangitis with autoimmune pancreatitis not responsive to steroid therapy. JOP; 2010;11(1):58-60
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of advanced-stage sclerosing cholangitis with autoimmune pancreatitis not responsive to steroid therapy.
  • CONTEXT: Autoimmune pancreatitis and sclerosing cholangitis associated with autoimmune pancreatitis respond well to steroid therapy.
  • Some criteria used for the differential diagnosis of autoimmune pancreatitis and sclerosing cholangitis with autoimmune pancreatitis include the response to a steroid trial.
  • CASE REPORT: A 68-year-old woman was diagnosed as having type 3 sclerosing cholangitis with autoimmune pancreatitis four years after clinical onset.
  • Seven years after clinical onset, imaging findings revealed multiple pancreatic stones in an atrophic pancreas, stenosis of the main pancreatic duct in the head of the pancreas and upstream dilatation and a longer stretch of stenosis in the hilar hepatic region.
  • We tried steroid therapy in an attempt to ameliorate stenosis of both the bile duct and the pancreatic duct and prevent further progression.
  • Neither lesion responded to steroid therapy.
  • CONCLUSION: Advanced-stage sclerosing cholangitis with autoimmune pancreatitis may sometimes be unresponsive to steroid therapy, and this should be borne in mind when attempting a steroid trial for the diagnosis of sclerosing cholangitis with autoimmune pancreatitis.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Cholangitis, Sclerosing / drug therapy. Pancreatitis / drug therapy. Steroids / therapeutic use
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Disease Progression. Female. Humans. Treatment Failure

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065555.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


8. Onoue S, Katoh T, Chigira H, Shibata Y, Matsuo K, Suzuki M: Carcinoma of the head of the pancreas. Hepatogastroenterology; 2002 Mar-Apr;49(44):549-52
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the head of the pancreas.
  • BACKGROUND/AIMS: Extended radical surgery might provide a survival advantage for patients with carcinoma of the head of the pancreas.
  • METHODOLOGY: Between January 1980 and December 1999, 144 patients with carcinoma of the head of the pancreas were treated in a community hospital setting, of whom 69 patients who underwent radical surgery were retrospectively reviewed.
  • No patients received adjuvant chemotherapy or radiotherapy.
  • RESULTS: The surgical resection rate was 47.9% with a surgical mortality rate of 4.3% during this period.
  • The overall 5-year survival rate after radical surgery was 16.1% with a median survival of 12 months.
  • Long-term survivors had less than two positive lymph nodes in the posterior pancreatic head.
  • CONCLUSIONS: Extended radical surgery did not prolong survival for patients with carcinoma of the head of the pancreas.
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11995493.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg; 2001 Mar-Apr;5(2):121-30
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.
  • We examined the effect of preoperative chemoradiotherapy on the ability to obtain pathologically negative resection margins in patients undergoing pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas.
  • Between 1987 and 2000, 100 patients underwent Whipple resection with curative intent for primary adenocarcinoma of the head of the pancreas.
  • Pathologic assessment of six margins (proximal and distal superior mesenteric artery, proximal and distal superior mesenteric vein, pancreas, retroperitoneum, common bile duct, and hepatic artery) was undertaken by either frozen section (pancreas and common duct) or permanent section.
  • A margin was considered positive if tumor was present less than 1 mm from the inked specimen.
  • Of the 100 patients treated, 47 (47%) underwent postoperative radiation and chemotherapy (group I) and 53 (53%) received preoperative chemoradiotherapy (group II) with either 5-fluorouracil (32 patients) or gemcitabine (21 patients).
  • Patient demographics and operative parameters were similar in the two groups, with the exception of preoperative tumor size (CT scan), which was greater in group II (P < 0.001), and number of previous operations, which was greater in group II (P < 0.0001).
  • Statistical analysis of the number of negative surgical margins clear of tumor was performed using Fisher's exact test.
  • All patients (100%) had six margins assessed for microscopic involvement with tumor.
  • In the preoperative therapy group, 5 (7.5%) of 53 patients had more than one positive margin, whereas 21 (44.7%) of 47 patients without preoperative therapy had more than one margin with disease extension (P < 0.001).
  • Additionally, only 11 (25.6%) of the 47 patients without preoperative therapy had six negative margins vs. 27 (50.9%) of 53 in the group receiving preoperative therapy (P = 0.013).
  • Similarly, a strong trend toward improved disease-free and overall survival is seen in patients with a single positive margin vs. multiple margins.
  • However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Sep;206(3):366-73 [2820322.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):79-84 [3121546.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):65-71 [3015059.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Cancer. 1976 Mar;37(3):1519-24 [1260670.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):227-32 [7799024.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):96-101 [1509287.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):117-22 [10030424.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • (PMID = 11331473.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Miura T, Endo Y, Matumoto Y, Ikeda H: [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival]. Gan To Kagaku Ryoho; 2000 Oct;27(12):1794-800
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
  • Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented.
  • A patient with cancer in the pancreatic head with accompanying extensive metastasis in both hepatic lobes was treated by sub selective aortic infusion of 5-FU and MMC with microwave hyperthermia.
  • Both the cancer in the pancreatic head and the liver metastasis showed complete remission for 16 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Liver Neoplasms / secondary. Microwaves / therapeutic use. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Remission Induction. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11086415.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • CT is the most important way of diagnosis and the combination of B-ultrasound, CT and MRI may improve the rate of diagnosis up to 96.6%.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Sugimoto K, Okada K, Nakahira S, Okamura S, Miki H, Nakata K, Suzuki R, Yoshimura M, Uji K, Yoshida A, Tamura S: [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine]. Gan To Kagaku Ryoho; 2009 Feb;36(2):321-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
  • We report a case of pancreas head cancer with liver metastasis treated with uracil-tegafur (UFT) and gemcitabine combined chemotherapy.
  • The histopathological diagnosis was adenocarcinoma, so we inserted a self-expandable metallic stent (EMS) in this inoperable pancreas head cancer.
  • We performed 9 courses of UFT and gemcitabine (GEM) combination chemotherapy.
  • Renewed liver metastases did not appear, and the pancreas head tumor partially responded.
  • After treatment with an additional 11 courses of chemotherapy, he took S-1 orally because of a tumor recurrence.
  • Combination chemotherapy and surgery enhanced the survival benefit in this case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223756.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • Three courses of intra-arterial infusion of mitomycin C and microspheres (1000 mg) resulted in regression of her tumor and a decrease of tumor marker levels.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • As her metastases were controlled for about 7 months, hepatic arterial infusion of mitomycin C and degradable starch microspheres appears to be useful for treating liver metastasis of pancreatic cancer, but careful attention should be paid to the risk of severe complications such as bile duct necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


14. Tanaka H, Takamori H, Eto S, Ozaki N, Akaboshi S, Nakahara O, Ida S, Furuhashi S, Abe S, Horino K, Beppu T, Baba H: [Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1783-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer].
  • Imagings revealed cancer of the head of the pancreas.
  • We performed pancreaticoduodenectomy for pancreatic cancer.
  • The histopathological diagnosis was tubular adenocarcinoma of the pancreas.
  • As a postoperative adjuvant chemotherapy, gemcitabine hydrochloride (GEM) was injected at a dose of 800mg/m2 once a week.
  • With these conservative treatments, she recovered completely.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Hepatic Encephalopathy / chemically induced. Hepatitis B / complications. Liver / injuries. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Amino Acids, Branched-Chain / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lactulose / therapeutic use. Tomography, X-Ray Computed


15. Kobayashi M, Kasakura Y, Fujii M, Mochizuki F, Kochi M, Eguchi T, Imai S: [Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report]. Gan To Kagaku Ryoho; 2001 Apr;28(4):527-30
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
  • A 56-year-old male was admitted for treatment of advanced gastric cancer.
  • The patient was diagnosed as having an unresectable advanced gastric cancer because cancer cells had invaded the pancreas head and there were metastatic lymph nodes.
  • The patient underwent preoperative chemotherapy (FLEP: intra-arterial infusion of CDDP, ETP and intravenous infusion of 5-FU, LV).
  • The primary tumor and metastatic lymph nodes were reduced by three course of chemotherapy.
  • Preoperative chemotherapy using FLEP was performed in 15 patients with unresectable primary advanced gastric cancer.
  • This therapy resulted in significantly higher survival times.
  • In conclusion, FLEP has been shown to be effective for unresectable advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Infusion Pumps, Implantable. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Gastrectomy. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Preoperative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329789.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP regimen
  •  go-up   go-down


16. Tsuruta K, Okamoto A, Egawa N, Kamisawa T, Karasawa K, Takahashi T: Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer. J Surg Oncol; 2001 Nov;78(3):202-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer.
  • BACKGROUND AND OBJECTIVES: The combination of 5-fluorouracil and radiotherapy is thought to be the most effective treatment for locally unresectable pancreatic carcinoma.
  • We assessed the survival benefits of oral adjuvant chemotherapy with doxifluridine (5'-DFUR) following radiotherapy for patients with the disease.
  • METHODS: Thirty-five consecutive patients who underwent bypass surgery and radiotherapy for localized advanced unresectable adenocarcinoma of the pancreas head were retrospectively reviewed in regard to disease progression and survival.
  • Ten of the 35 patients underwent adjuvant chemotherapy with 5'-DFUR after radiotherapy in an outpatient setting.
  • The 1-, 2-, and 3-year survivals for patients treated with the adjuvant chemotherapy after radiotherapy were 50, 40, and 30%, respectively (P = 0.0069, log-rank test).
  • The elevation of tumor markers was delayed (P = 0.0346) and local control rate was improved (P = 0.0475) in patients with chemotherapy.
  • Multivariate analysis demonstrated that the adjuvant chemotherapy with 5'-DFUR was a significant independent prognostic factor as well as tumor size.
  • CONCLUSIONS: The adjuvant chemotherapy with 5'-DFUR following radiotherapy led to a significant prolongation of the survival for patients with unresectable localized pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Floxuridine / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Administration, Oral. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survivors

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745808.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; V1JK16Y2JP / doxifluridine
  • [Number-of-references] 21
  •  go-up   go-down


17. Denno R, Sasada T, Kanai M, Takabayashi A: Phase II trials of pancreatic and hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) in patients with advanced pancreatic cancer with or without liver metastasis. J Clin Oncol; 2004 Jul 15;22(14_suppl):4140

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of pancreatic and hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) in patients with advanced pancreatic cancer with or without liver metastasis.
  • : 4140 Background: Liver metastasis is a common progression of pancreatic cancer.
  • The purpose of this study was to examine the efficacy and safety of a modality therapy consisting of pancreatic and hepatic arterial infusion of 5-FU and CDDP in patients with advanced pancreatic cancer with or without liver metastasis.
  • METHODS: 12 patients with unresectable pancreatic cancer were enrolled in this study.
  • 8 patients had locally advanced pancreatic cancer with no distant metastases (Group A).
  • 4 patients had advanced pancreatic cancer with no distant metastases except to the liver (Group B).
  • To restrict the blood flow into the pancreas and the liver, the peripancreatic artery (ex. dorsal pancreatic artery) were embolized superselectively with microcoils.
  • The tip of the catheter was placed in the proper hepatic artery and the side hole was placed in the gastroduodenal artery for the patients of pancreas head cancer.
  • The splenic artery and the common hepatic artery were used for the patients of pancreas body or tail cancer.
  • The patients of Group A received both hepatic and pancreatic arterial injection chemotherapy to prevent liver metastasis.
  • The arterial infusion chemotherapy consisted of 5-FU 250 mg/sqm administration as a 24-hr continuous arterial infusion and a bolus injection of CDDP 5mg/sqm three times a week for two weeks to all 12 patients.
  • Consequently, 8 of 12 patients were administered 5-FU 600mg/sqm as a 5-hr continuous arterial infusion weekly.
  • Median survival time was 16.3 months for Group A and 6.1 months for Group B.
  • One of Group A had liver metastasis after this treatment.
  • CONCLUSIONS: In patients with unresectable pancreatic cancer, hepatic and pancreatic arterial injection chemotherapy after hemodynamic change is effective to treat main pancreatic tumor and to prevent liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Oshiro A, Nagasaki A, Nakachi A, Uchima N, Hasegawa H, Nakazato T, Nakamoto M, Kinjo N, Kinjo F, Taira N, Masuda M, Takasu N: [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1169-73
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy].
  • A 65-year-old woman with diabetes mellitus was hospitalized for heart failure and anemia in August 2001, and recovered with conservative treatment.
  • Abdominal CT scan demonstrated tumor involvement in the pancreas head.
  • The diagnosis of a diffuse large B-cell lymphoma, clinical stage IIE, was made by endoscopic biopsy.
  • Although surgical resection of the localized intestinal tumor would have been a common choice for initial treatment, polychemotherapy was selected; the patient had diabetes mellitus and preferred polychemotherapy to surgical operation.
  • Because of bulky intestinal mass, transmural disease and sensitive histological type, standard-dose chemotherapy was considered to include a high risk of intestinal perforation.
  • We performed dose-escalating chemotherapy: A half dose of THP-COP (pirarubicin, cyclophosphamide, vincristine) was given at the start in October 2001, 60% THP-COP as the next cycle, 80% THP-COP as the 3rd cycle and thereafter.
  • Without serious complications of the intestine, she received a total of 6 cycles of chemotherapy and subsequent involved field radiation.
  • There has been no evidence of recurrence of disease 14 months from the start of chemotherapy.
  • When conditions make surgical treatment difficult, dose-escalating chemotherapy in a treatment cycle may be considered as an alternative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


19. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • A resected case of gastric cancer is described.
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • Radical resection was not indicated, and we administered the following combination chemotherapy with TS-1 and CDDP.
  • 120 mg/day of TS-1 was orally administered for 3 weeks followed by 2 drug-free weeks as 1 course and 9 5 mg (60 mg/m(2)) of CDDP was administered intravenously on day 8.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Kodjikian L, Grange JD, Rivoire M: Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):622-4
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
  • METHODS: A 30-year-old patient, treated for choroidal melanoma by proton beam therapy, was semiannually followed by abdominal ultrasonography.
  • Two years after initial treatment, a total body computed tomography scan suggested the diagnosis of isolated liver metastases.
  • RESULTS: Multiple wedge resections and postoperative intra-arterial chemotherapy with fotemustine were performed.
  • After 4 years, a metastatic nodule in the head of the pancreas was detected and surgically removed.
  • The patient finally died of carcinomatous meningitis 9 years of first treatment of metastases.
  • CONCLUSIONS: In the present case, the surgical control of liver metastases associated with intra-arterial chemotherapy prolonged the quality and length of life with progressive disease extension to other organs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatectomy / methods. Liver Neoplasms / mortality. Melanoma / mortality. Uveal Neoplasms / mortality
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Fatal Outcome. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Neoplasm Metastasis. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):127-30 [9591028.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S27-30 [9849406.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):122-9 [14692032.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Arch Ophthalmol. 1984 Jan;102(1):80-2 [6200095.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2219-23 [7848381.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):207-8; author reply 208 [15222009.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1561-8 [11013372.001]
  • [Cites] Am J Ophthalmol. 1998 Mar;125(3):407-9 [9512169.001]
  • (PMID = 15650857.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 7GR28W0FJI / Dacarbazine; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


21. Ho Kim D, Shiozawa S, Tsuchiya A, Usui T, Inose S, Aizawa M, Yoshimatsu K, Katsube T, Naritaka Y, Ogawa K: [A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jan;35(1):133-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer].
  • The patient was a 48-year-old male who underwent pancreaticoduodenectomy with portal vein resection for ductal adenocarcinoma of the pancreas head.
  • Twenty-two days after operation, adjuvant chemotherapy with gemcitabine(1,000 mg/m(2) on days 1, 8 and 15 every 4 weeks)was started.
  • During three courses of chemotherapy, no adverse event of WHO grade 2 or more was observed.
  • Seven days after the last infusion, fever and consciousness disorder emerged without respiratory symptoms.
  • Oxygenation and respiratory support were immediately given, and steroid pulse therapy with 1,000 mg/day of methylprednisolone was started.
  • The review of reported cases showed the effectiveness of corticosteroid therapy for pulmonary toxicity due to the agent.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Lung Diseases, Interstitial / complications. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195543.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


22. Tanigawa T, Hasuike Y, Yamada M, Fujiwara S, Murata H: [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2085-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of infected pseudo-aneurysm after intra-arterial chemotherapy].
  • Computed tomography (CT) showed a mass in the head of the pancreas and a dilated bile duct.
  • As adjuvant chemotherapy, the patient received a hepatic arterial infusion with 5-FU to prevent liver metastasis.
  • A catheter was placed in the right femoral artery and intra-arterial chemotherapy was carried out for one week.
  • After the completion of chemotherapy, swelling and redness of the right inguinal region was observed.
  • Despite intravenous antibiotic therapy for 2 days, bleeding and pus discharge at the catheter root were observed.
  • In such cases, it is advisable to drain the infected pseudo-aneurysm following a prompt diagnosis, and perform a secondary bypass operation.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Male. Middle Aged. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037331.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Yoneto T, Yoshikawa K, Fujii Y: [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine]. Gan To Kagaku Ryoho; 2005 Jan;32(1):99-102
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
  • A 79-year-old female patient was referred to our hospital for treatment of a recurrent gallbladder cancer.
  • Before admission, she had undergone expanded cholecystectomy and had been treated successfully with 5-FU for 3 years to suppress the tumor growth in intraperitoneal lymph nodes.
  • The recurrence of the tumor in lymph nodes near the pancreas head was demonstrated by computer tomography.
  • We tried a course of a combination chemotherapy consisting of CPT-11 and CDDP (40 mg CPT-11/body/day on day 1 and 10 mg CDDP/body/day on day 2-5) to reduce the size of the nodes.
  • Then, we repeated a total of 8 courses of the therapy at 4-week intervals.
  • So, we substituted gemcitabine (1 g/body/day) for the combination chemotherapy with expandable metallic stent implantation to drain the bile.
  • As a result, metastatic lymph nodes were reduced in size and the dilatation of the interhepatic bile duct disappeared.
  • Thereafter, the patient was given an additional 20 courses of gemcitabine therapy at 2-week intervals as an outpatient.
  • However, the patient died of liver metastasis 8 years after operation and 6 years after she started chemotherapy for the recurrence.
  • She maintained a good quality of life during that time.
  • The present case suggests that combination of chemotherapy protocols is effective for clinical management of gallbladder cancer recurrence, which is generally considered to be difficult to manage with chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Survivors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675592.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Kim DH, Shiozawa S, Tsuchiya A, Usui T, Inose S, Aizawa M, Yoshimatsu K, Katsube T, Naritaka Y, Ogawa K: [Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1229-31
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report].
  • We present a case successfully treated with gemcitabine for residual tumor after extra hepatic bile duct resection with positive surgical margin.
  • The patient was a 77-year-old male who was diagnosed as having a common bile duct cancer.
  • Extra hepatic bile duct resection was performed, but intraoperative pathology diagnosed the surgical margin of duodenal-side bile duct was positive for cancer.
  • Although additional resection of bile duct was done, pathological diagnosis resulted in positive margin again.
  • Adjuvant chemotherapy with gemcitabine(800 mg/m2 on days 1, 8 and 15 every 4 weeks)was started at the seventh postoperative day.
  • A residual lesion was shown in the pancreas head by abdominal CT after 2 courses of chemotherapy.
  • The chemotherapy has been continued up to the present(3 years and 5 months after surgery).
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Aged. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


25. Seki H, Ozaki T, Takaki S, Ooi H, Oda J, Shiina M: Using slow-infusion MR arteriography and an implantable port system to assess drug distribution at hepatic arterial infusion chemotherapy. AJR Am J Roentgenol; 2003 Mar;180(3):681-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using slow-infusion MR arteriography and an implantable port system to assess drug distribution at hepatic arterial infusion chemotherapy.
  • SUBJECTS AND METHODS: In 37 patients with liver metastases who had implantable port systems for hepatic arterial infusion chemotherapy, slow-infusion MR arteriography using an infusion rate of 10 mL/hr through an implantable port and CT arteriography using an injection rate of 0.7 mL/sec were performed.
  • In eight patients, the patterns of extrahepatic perfusion into the duodenum and the pancreas head differed on slow-infusion MR arteriography from those seen on CT arteriography.
  • CONCLUSION: We believe that slow-infusion MR arteriography reflects the actual distribution of infused drugs more accurately than CT arteriography.
  • When clinical complications occur during treatment, slow-infusion MR arteriography should be used to assess perfusion abnormalities.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Catheters, Indwelling. Hepatic Artery / radiography. Liver Neoplasms / drug therapy. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12591674.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Takagi T, Ueda N, Kanemoto H: [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1453-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)].
  • The patient was a 66-year-old female with Borrmann's type 4 gastric cancer complicated by metastasis to the liver and invasion of the head of the pancreas.
  • One course of chemotherapy was defined as 3 weeks of drug administration(TS-1 100 mg/body/day po for 21 days + CDDP 9 0 mg/body/day by iv drip on day 8), followed by a 2-week rest period.
  • Chemotherapy was started 13 days after the operation, and it was possible to continue it for 7 courses.
  • TS-1/CDDP therapy improved the patient's general condition.
  • The tumor marker levels were also decreased.
  • However, the efficacy of treatment began to decline,and ascites gradually developed during the fourth course of therapy.
  • The treatment regimen was then switched to TS-1 100 mg/body/day po for 14 days, followed by a 14-day rest period, combined with PTX 9 0 mg/body/day iv drip on day 1 and day 15, while the ascites was being controlled.
  • However, PTX was switched to CPT-11 because of gradual progression of peripheral neuropathy as a side effect of chemotherapy, and the patient subsequently died without any improvement in symptoms.
  • This report describes a case of advanced gastric cancer treated by combination chemotherapy with TS-1 as a key drug, which resulted in a long survival (1 year and 5 months)and improvement in quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pancreatic Neoplasms / pathology. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227747.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Nio Y, Itakura M, Koike M, Omori H, Hashimoto K, Yano S, Higami T: A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment. Anticancer Res; 2003 Mar-Apr;23(2C):1795-801
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment.
  • Obstructive jaundice is a terminal symptom of gastric cancer.
  • A 45-year-old female patient had a recurrent gastric cancer at the pancreas head and it caused obstructive jaundice.
  • She was treated with percutaneous transhepatic cholangio-drainage, followed by radiotherapy and chemotherapy with cisplatin, epirubicin and 5-FU, which resulted in a prominent response and a self-expandable metallic stent was placed into the bile duct.
  • After 11 months, however, the tumor recurred and the bile duct was obstructed again by an invading tumor.
  • She was retreated with percutaneous transhepatic cholangio-drainage for jaundice, followed by chemotherapy with oral TS-1.
  • Her recurrent tumor dramatically responded again, and cholangioscopic microwave coagulation therapy was applied for the first time through a cholangio-drainage route and an additional metallic stent was inserted into the bile duct.
  • After these therapies she has been disease--free for more than 2 years.
  • In conclusion, the placement of a self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and TS-1 was very effective in managing the obstructive jaundice due to the local recurrence of gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cholestasis, Extrahepatic / therapy. Microwaves / therapeutic use. Neoplasm Recurrence, Local / complications. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stents. Stomach Neoplasms / complications. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Bile Ducts / surgery. Cautery / methods. Combined Modality Therapy. Drainage. Drug Combinations. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820461.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Pandya G, Dixit R, Shelat V, Dixit K, Shah N, Shah K: Obstructive jaundice: a manifestation of pancreatic tuberculosis. J Indian Med Assoc; 2007 Mar;105(3):133-4, 136
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice: a manifestation of pancreatic tuberculosis.
  • Tuberculosis of the pancreas is extremely rare and is most often associated with miliary tuberculosis or occurs in the immunocompromised patients.
  • A case of isolated pancreatic tuberculosis in an immunocompetent patient is presented with constitutional symptoms and obstructive jaundice.
  • Ultrasonography and computerised tomography showed a mass lesion in the head of pancreas.
  • Histological examination of the peripancreatic lymph node and fine needle aspiration cytology from the head of pancreas confirmed the diagnosis following laparotomy.
  • Patient recovered following the administration of antituberculosis chemotherapy.
  • [MeSH-major] Antitubercular Agents / administration & dosage. Jaundice, Obstructive / etiology. Pancreatic Diseases / complications. Tuberculosis / complications
  • [MeSH-minor] Adult. Diagnostic Imaging. Drug Therapy, Combination. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824465.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


29. Takeyama O, Usui Y: [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases]. Gan To Kagaku Ryoho; 2005 Feb;32(2):247-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
  • Abdominal CT scan and ultrasonography both revealed a tumor in the head of the pancreas.
  • The patient was diagnosed as having advanced pancreatic cancer with multiple lung metastases.
  • The primary tumor showed a partial response to the administration of gemcitabine 1,000 mg/m2 on days 1, 8 and 15 of a 28-day cycle.
  • Concurrent treatment with 5-fluorouracil (200 mg/day) was efficacious against the lung metastases.
  • One year later the pancreatic and lung tumors had enlarged, and cisplatin (20 mg/body) was added to the protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Quality of Life. Survivors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic Cancer Registry in Japan: 20 years of experience.
  • The prognosis of pancreatic cancer is defined by the histology and extent of disease.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • The overall resectability rate of pancreatic cancer is 40% in Japan.
  • Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084961.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology; 2006;6(4):306-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
  • The first discovery of a cerebellar metastasis of pancreatic carcinoma in a living patient is described.
  • Two years earlier the patient had undergone a pancreaticoduodenectomy for an adenocarcinoma of the head of the pancreas with a lymph node metastasis.
  • After complete surgical removal of the tumor, he underwent adjuvant chemoradiation.
  • Clinical evaluation revealed an intracranial tumor without signs of pancreatic recurrence.
  • The tumor was surgically removed.
  • One year later the patient developed multiple brain metastases and he is currently undergoing gemcitabine-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / radiography. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Male. Pancreaticoduodenectomy. Recurrence. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636605.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


32. Tanaka T, Yamamoto K, Sho M, Nishiofuku H, Inoue M, Sueyoshi S, Anai H, Sakaguchi H, Nakajima Y, Kichikawa K: Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. J Vasc Interv Radiol; 2010 Jan;21(1):116-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model.
  • PURPOSE: The purpose of this study was to investigate the potential pharmacokinetic advantage of pancreatic arterial infusion chemotherapy of 5-fluorouracil (5-FU) with temporary unification of the pancreatic blood supply for advanced pancreatic cancer in an animal model.
  • At 0, 10, 30, and 60 minutes after drug infusion, the concentrations of 5-FU were measured in plasma and tissues including the liver, pancreatic head, pancreatic uncinate process, and duodenum.
  • Areas under the concentration-time curve (AUCs) were calculated and statistically compared.
  • RESULTS: The temporary unification of the pancreatic blood supply by converting from dual blood supply through the celiac artery and SMA into a single celiac arterial supply was confirmed by dye injection.
  • Mean AUCs in the pancreas head and liver were significantly higher for groups II and III compared with group I (P < .05).
  • In addition, the AUC in the pancreatic uncinate process was significantly higher for group III compared with groups I and II (P < .05).
  • CONCLUSIONS: Pancreatic arterial infusion chemotherapy allows efficient regional drug delivery into the pancreas and liver.
  • Importantly, the unification of the pancreatic blood supply may be required to induce maximum efficacy of arterial infusion chemotherapy for the tumor in the pancreatic uncinate process.
  • [MeSH-major] Arteries / metabolism. Arteries / surgery. Fluorouracil / pharmacokinetics. Pancreas / blood supply. Pancreas / metabolism
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacokinetics. Humans. Infusions, Intra-Arterial. Metabolic Clearance Rate. Organ Specificity. Swine. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20123197.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Fujii M, Sato H, Ogasawara T, Ando T, Tsujii S, Nagahori J, Komatsu Y, Matsuoka A: [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1987-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy].
  • A 55-year-old man underwent a pylorus-preserving pancreatoduodenectomy in August 2006 because of acinar cell carcinoma of the head of the pancreas.
  • Since abdominal CT revealed multiple liver metastases, we started systemic chemotherapy with gemcitabine (1,400 mg/body, day 1, 8, 15/q4w) in October 2006.
  • At the beginning of this treatment, it seemed to be a stable disease, but CT revealed tumor progression in January 2007.
  • Despite the change to oral chemotherapy with S-1 (100 mg/body, day 1-14/q3w), tumors were markedly enlarged in March 2007.
  • Therefore, we selected combination chemotherapy with oral S-1 and hepatic arterial infusion of CDDP (50 mg/body) as third-line.
  • After 6 months of treatment, abdominal CT revealed marked shrinkage of tumors, accompanied by a decrease in AFP level.
  • Though the patient died of hepatic failure in July 2009 (33 months after recurrence), he spent most of his time at home and worked as usual.
  • We suggest that combination chemotherapy with oral S-1 and intra-arterial CDDP can be effective treatments for pancreatic acinar cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Fatal Outcome. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Glaser M, Roskar Z, Skalicky M, Krajnc I: Cystic dystrophy of the duodenal wall in a heterotopic pancreas. Wien Klin Wochenschr; 2002 Dec 30;114(23-24):1013-6
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic dystrophy of the duodenal wall in a heterotopic pancreas.
  • Cystic dystrophy of the duodenal wall in heterotopic pancreas is a rare disease affecting younger men in particular.
  • On account of its difficult diagnosis and nonspecific signs, it was first described in 1970.
  • A 51-year-old male patient was admitted for clarification of several months of severe pain in the upper abdomen accompanied by weight-loss, and due to ultrasonically established suspicion of carcinoma in the head of the pancreas.
  • Ultrasound examination showed cystic changes in the duodenal wall and in the vicinity of the head of the pancreas.
  • Only with the aid of endoscopic ultrasound, could bizarre cystic changes in the submucosa of the duodenal wall be detected, which was also confirmed by computer tomography.
  • Cystic changes with fibrosis, pancreatic ducts and lobi without anatomic or vascular connection to the pancreas are found.
  • Prior to the introduction of imaging techniques such as endoscopic ultrasonography, computer tomography and nuclear magnetic resonance, the diagnosis could only be made by means of an operative procedure.
  • Treatment is primarily surgical; smaller cysts can be treated by endoscopic fenestration.
  • Pharmacological treatment with somatostatin is rarely performed.
  • [MeSH-major] Choristoma. Cysts. Duodenal Diseases. Pancreas
  • [MeSH-minor] Abdominal Pain / drug therapy. Abdominal Pain / etiology. Endoscopy. Hormones / administration & dosage. Hormones / therapeutic use. Humans. Injections, Subcutaneous. Male. Middle Aged. Somatostatin / administration & dosage. Somatostatin / therapeutic use. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635471.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Hormones; 51110-01-1 / Somatostatin
  •  go-up   go-down


35. Hisama S, Kimura M, Nishimura T, Matsushita H, Okamura S, Saitoh S, Shimokawa Y, Arakawa A, Toyama H, Tanaka Y: [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1337-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
  • A 65-year-old man suffering from acute pancreatitis underwent MRI scanning, which revealed a low signal on the T1 and T2 sequences, and hypovascularity in arterial phase in the head of the pancreas.
  • FDG-PET was highly suggestive of pancreatic cancer (T4N1M0, Stage IVa) with lymph node metastasis.
  • He was treated with systemic chemotherapy using gemcitabine (GEM) followed by radiotherapy.
  • His symptoms gradually improved with a reduction in size of the primary lesion.
  • The patient has been receiving systemic chemotherapy using S-1 without recurrence.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Remission Induction. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


36. Koizumi M, Sata N, Shimura K, Tsukahara M, Yoshizawa K, Kurihara K, Hyodo M, Yasuda Y, Nagai H: [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2133-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
  • A 76-year-old man developed jaundice and was hospitalized in January 2002.
  • A 3 cm tumor was found in the head of the pancreas by abdominal CT, and the patient underwent laparotomy.
  • The tumor was histologically diagnosed as a well-differentiated adenocarcinoma, and showed extensive invasion to the portal vein (T4NXM 0 Stage IV a).
  • On the basis of a drug sensitivity test, chemotherapy with 800 mg/m2/week gemcitabine was administered.
  • The patient showed prolonged NC without any symptoms for 22 months, although the CEA and DUPAN-2 levels gradually increased during this time and massive ascites were detected in a routine abdominal CT at 22 months postsurgery.
  • The patient died after 25 months of chemotherapy.
  • Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Screening Assays, Antitumor. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


37. Kalil AN, Reck dos Santos PA, Azambuja DB, Beck PE: A case of retroperitoneal lymphoma presenting as pancreatic tumor. Hepatogastroenterology; 2004 Jan-Feb;51(55):259-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of retroperitoneal lymphoma presenting as pancreatic tumor.
  • We describe a case of non-Hodgkin's lymphoma arising in the peripancreatic retroperitoneal lymph node and extending into the pancreatic parenchyma.
  • Abdominal ultrasonogram and computed tomography of the abdomen showed an mass in the head of pancreas with absence of extrapancreatic disease and no direct tumor extension to the portal vein or superior mesenteric artery.
  • Laparotomy demonstrated a large pancreatic mass with no obstruction of common bile duct or encasement of portal vein and superior mesenteric artery and a pancreaticoduodenectomy was performed.
  • He received chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone.
  • The patient is alive and in remission with a follow-up time of 24 months.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011880.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


38. Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H: Seminoma metastases mimicking primary pancreatic cancer. Onkologie; 2002 Aug;25(4):371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seminoma metastases mimicking primary pancreatic cancer.
  • BACKGROUND: A case of seminoma clinical stage III, arising from the right testis and mimicking a primary pancreatic malignancy is reported.
  • Abdominal CT scan showed a tumor in the head of the pancreas and multiple pathologically enlarged peripancreatic lymph nodes.
  • A laparoscopic biopsy out of a suspicious lesion of the head of the pancreas and a surrounding lymph node was done.
  • 4 cycles of chemotherapy including cisplatinum, etoposide and bleomycin led into complete response that is still ongoing.
  • CONCLUSION: This case shows a seminoma with metastases at retroperitoneal site, mimicking a primary pancreatic neoplasm.
  • It provides an example of the possibility of an uncommon clinical appearance of seminoma metastases and again underlines the importance of exact radiological and histopathological examination to distinguish between curable and incurable tumor.
  • [MeSH-major] Pancreatic Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Pancreas / pathology. Tomography, X-Ray Computed


39. Faraj W, Jamali F, Khalifeh M, Hashash J, Akel S: Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature. Eur J Pediatr Surg; 2006 Oct;16(5):358-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary neoplasm of the pancreas in a 12-year-old female: case report and review of the literature.
  • Solid pseudopapillary neoplasms of the pancreas (SPNP) are rare pancreatic tumors that occur predominantly in young women, with very few cases reported in men.
  • While the origin of the tumor may be unclear, it is characterized by a distinct histological appearance and a clinical course highlighting its low malignant potential.
  • The role of chemotherapy and radiation therapy in the management of SPNP is still controversial.
  • We report here on an unusual occurrence of SPNP in the area of the head of the pancreas in a 12-year-old female treated by pancreatico-duodenectomy, together with a review of the literature.
  • [MeSH-major] Pancreatic Neoplasms / surgery
  • [MeSH-minor] Child. Female. Humans. Pancreaticoduodenectomy. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160784.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


40. Eyigor C, Pirim A, Uyar M: Should interventional pain management in patients with pancreatic cancer be guided by tumor localization? J BUON; 2010 Oct-Dec;15(4):715-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should interventional pain management in patients with pancreatic cancer be guided by tumor localization?
  • PURPOSE: to investigate the impact of pancreatic cancer localization in relation to the response to different interventional pain management methods and determine the method most suitable for satisfactory pain control.
  • Patients were allocated into 2 groups according to the tumor localization, namely group 1 (n=61; patients with pancreatic cancer confined to the head of pancreas), and group 2 (n=55; patients with pancreatic cancer confined to the body or tail of pancreas).
  • CONCLUSION: pain palliation could be achieved by sympathetic block in patients with cancer localized in the head of pancreas while patients with tumor localized in the body and tail experienced sufficient pain palliation by spinal analgesia rather than sympathetic block.
  • [MeSH-major] Anesthetics, Local / therapeutic use. Pain Measurement. Pain, Intractable / drug therapy. Pancreatic Neoplasms / complications
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Nerve Block. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21229635.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anesthetics, Local
  •  go-up   go-down


41. Snajdauf J, Rygl M, Petru O, Kalousova J, Kuklova P, Mixa V, Keil R, Hribal Z: Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children. Eur J Pediatr Surg; 2009 Dec;19(6):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children.
  • AIM OF STUDY: Aim of the study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors of the head of the pancreas.
  • METHODS: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results.
  • In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved.
  • Patients with body and tail involvement underwent distal pancreatic resection.
  • In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed.
  • She developed a biliary fistula which closed after three weeks with endoscopic stenting.
  • One patient with head resection developed a biliary fistula which closed after two weeks of stenting.
  • One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively.
  • All patients are alive without tumor recurrence at 6 months to 16 years after operation.
  • CONCLUSION: SPTP is a rare pancreatic tumor with a low degree of malignancy.
  • No perioperative chemotherapy is necessary.
  • Therefore duodenal resection in cases of SPTP in the head of the gland seems too invasive and mutilating.
  • [MeSH-major] Biliary Fistula / etiology. Carcinoma, Papillary / surgery. Duodenum. Pancreatectomy / adverse effects. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19821226.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Ohata R, Okazaki T, Ishizaki Y, Fujimura J, Shimizu T, Lane GJ, Yamataka A, Kawasaki S: Pancreaticoduodenectomy for pancreatoblastoma: a case report and literature review. Pediatr Surg Int; 2010 Apr;26(4):447-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging studies showed a solid 4 cm tumor in the head of the pancreas and two lesions in the liver.
  • After five courses of chemotherapy, the primary tumor was completely resected with pancreaticoduodenectomy (PD) and Child's pancreaticobiliary tract reconstruction.
  • [MeSH-major] Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Biopsy, Needle. Child. Follow-Up Studies. Humans. Male. Pancreas / surgery. Rare Diseases. Reconstructive Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2010 May;54(5):675-80 [19998473.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Pediatr Radiol. 2004 Jul;34(7):583 [15205844.001]
  • [Cites] J Pediatr Surg. 2006 Mar;41(3):596-8 [16516645.001]
  • [Cites] Lahey Clin Bull. 1955 Jul;9(5):155-9 [13252875.001]
  • [Cites] J Pediatr Surg. 1992 Oct;27(10):1315-7 [1328584.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):319-27 [6307069.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1734-6 [3115557.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] Histopathology. 1980 Jan;4(1):87-104 [6965487.001]
  • [Cites] Pancreatology. 2004;4(5):441-51; discussion 452-3 [15256806.001]
  • [Cites] Cancer. 1976 Mar;37(3):1508-18 [1260669.001]
  • [Cites] Surgery. 1984 Apr;95(4):420-6 [6710338.001]
  • [Cites] Diagn Cytopathol. 2001 Aug;25(2):118-21 [11477717.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):963-9 [6141001.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):201-5 [3048135.001]
  • [Cites] Acta Pathol Jpn. 1983 May;33(3):565-75 [6353853.001]
  • [Cites] Cancer. 1977 Jan;39(1):247-54 [188539.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6(6):369-72 [9007475.001]
  • [Cites] Arch Surg. 1970 Sep;101(3):370-5 [4194202.001]
  • [Cites] Am J Dis Child. 1974 Jul;128(1):101-4 [4834991.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Dec;29(12 ):845-7 [18090935.001]
  • [Cites] World J Surg. 1998 Aug;22(8):879-82 [9673563.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Ann Surg. 1957 Jun;145(6):864-70; discussions, 870-2 [13425296.001]
  • [Cites] Pancreas. 2007 Jan;34(1):92-5 [17198189.001]
  • [Cites] J Pediatr Surg. 2009 Jan;44(1):197-203 [19159743.001]
  • [Cites] World J Surg. 1986 Oct;10(5):851-9 [3022489.001]
  • [Cites] Med Pediatr Oncol. 1997 Sep;29(3):237 [9212854.001]
  • (PMID = 20165952.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  •  go-up   go-down


43. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg; 2007 Nov;11(11):1460-7; discussion 1467-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.
  • The natural history of pancreatic neuroendocrine tumors (PNET) remains poorly defined.
  • Our objectives were to examine the clinicopathologic features of PNETs, to assess treatment trends over time, and to identify factors associated with undergoing resection.
  • From the National Cancer Data Base (1985-2004), 9,821 patients were identified with PNETs.
  • Clinicopathologic features and treatment trends were examined.
  • Of the 3,851 (39.0%) patients who underwent pancreatectomy, 449 (11.7%) received adjuvant chemotherapy, and 254 (6.6%) received adjuvant radiation.
  • Patients were less likely to undergo resection if they were > 55 years old, had tumors in the head of the pancreas, tumors > or = 4 cm, or had distant metastases (P < 0.0001).
  • As PNETs have a better prognosis than adenocarcinoma, concerns regarding the morbidity and mortality of pancreatic surgery and neoplasms should not preclude resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jan 15;65(2):354-7 [2153046.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Ann Intern Med. 1949 Oct;31(4):624-7 [15390535.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] World J Surg. 2007 Mar;31(3):579-85 [17219270.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1806-10 [16085691.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):327-31 [16504877.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1806-9 [15188511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73 [16030115.001]
  • [Cites] ANZ J Surg. 2001 Aug;71(8):475-82 [11504292.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):962-9 [15525824.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Dig Surg. 2005;22(3):157-62 [16043962.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):469-72 [15313691.001]
  • [Cites] J Surg Oncol. 2004 Jan;85(1):1-3 [14696080.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 17846854.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Hsu JT, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, Chen MF: Adenosquamous carcinoma of the pancreas. Digestion; 2005;72(2-3):104-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas.
  • BACKGROUND/AIMS: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult.
  • Case reports of ASC of the pancreas are sporadic and have typically employed small series.
  • This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease.
  • METHODOLOGY: Seven patients (4 men and 3 women; age range 38-79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed.
  • The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2.
  • Three patients received postoperative adjuvant chemotherapy.
  • CONCLUSIONS: Patients with ASC present symptoms similar to those of adenocarcinoma of the pancreas.
  • Most patients had dismal prognosis despite aggressive surgery with or without adjuvant therapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16172546.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


45. Dang S, Atiq M, Saccente M, Olden KW, Aduli F: Isolated tuberculosis of the pancreas: a case report. JOP; 2009;10(1):64-6
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated tuberculosis of the pancreas: a case report.
  • CONTEXT: Pancreatic tuberculosis is a rare entity.
  • We hereby describe a case of pancreatic tuberculosis in an immunocompromized individual.
  • CASE REPORT: A fifty-year-old African-American gentleman with history of HIV non-compliant on anti-retroviral therapy presented with epigastric pain for five weeks duration.
  • CT scan of abdomen showed large necrotic node on the posterior aspect of the head of pancreas and multiple cystic masses adjacent to the pancreas.
  • Anti-tubercular therapy was initiated and resulted in gradual resolution of symptoms.
  • CONCLUSION: Pancreatic tuberculosis is rare and is frequently confused with pancreatic cancer on clinical presentation as well as on imaging studies.
  • Since it is a curable disease, accurate diagnosis is paramount CT or ultrasound guided biopsy is cornerstone of diagnosis.
  • Endoscopic ultrasound is now increasingly being used for obtaining tissue for diagnosis.
  • Anti-tubercular therapy is curative in majority of the cases.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Pancreatic Diseases / diagnosis. Tuberculosis / diagnosis
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. HIV-1. Humans. Male. Middle Aged. Mycobacterium tuberculosis / isolation & purification


46. Nimura Y: [Treatment of pancreatic cancer--surgical point of view]. Gan To Kagaku Ryoho; 2007 Jul;34(7):993-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pancreatic cancer--surgical point of view].
  • Although surgical techniques for pancreatic cancer have developed in a high level, the treatment results have not been improved and the 5 year survival rates after curative operation has been about 15% in Japan.
  • Retrospective studies on extended lymphadenectomy for ductal adenocarcinoma of the head of the pancreas revealed that extended surgery prolonged the survival for resected patients.
  • Finally, the clinical advantages of extended lymphadenectomy for pancreatic cancer was denied by several RCTs from Italy and U.S.A.
  • Although usefulness of radio/chemotherapy has been controversial, adjuvant chemotherapy with gemcitabin significantly prolonged the patients' survival after curative pancreatectomy.
  • Further development of multidisciplinary treatments for pancreatic cancer is expected.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Lymph Node Excision / methods. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637533.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 24
  •  go-up   go-down


47. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


48. Osti MF, Costa AM, Bianciardi F, De Nicolò M, Donato V, Silecchia G, Enrici RM: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori; 2001 Nov-Dec;87(6):398-401
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study.
  • AIMS AND BACKGROUND: To evaluate the efficacy of combined radiation therapy and continuous infusion of 5-fluorouracil in patients with locally advanced carcinoma of the pancreas.
  • METHODS: Between January 1992 and June 1999, 31 patients with locally advanced adenocarcinoma of the pancreas were treated in our Institute.
  • In 20 patients, the tumor (65%) was located in the head of the pancreas and in 11 (35%) in the body or tail; 13 cases also showed involved nodes.
  • Radiation therapy consisted in a median dose of 63 Gy in 33-36 fractions applied to the tumor and regional lymph nodes.
  • Chemotherapy with 5-fluorouracil in continuous infusion, 250 mg/m2 daily, was administered in the first and fifth week of the radiation therapy.
  • Thereafter, 22 patients received 3-10 cycles of adjuvant chemotherapy with same doses.
  • The toxicity of the treatment was scored according to WHO criteria.
  • All patients underwent nutritional assessment at the time of radiochemotherapy.
  • At the time of the study, 2 patients (6.4%) were surgically proven disease free.
  • Tumor down-staging and resectability rates were high, together with prolonged survival and a good quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989594.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


49. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones L, Wyld P, Gillams A, Hatfield AW: Photodynamic therapy for cancer of the pancreas. Gut; 2002 Apr;50(4):549-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for cancer of the pancreas.
  • BACKGROUND: Few pancreatic cancers are suitable for surgery and few respond to chemoradiation.
  • Photodynamic therapy produces local necrosis of tissue with light after prior administration of a photosensitising agent, and in experimental studies can be tolerated by the pancreas and surrounding normal tissue.
  • AIMS: To undertake a phase I study of photodynamic therapy for cancer of the pancreas.
  • PATIENTS: Sixteen patients with inoperable adenocarcinomas (2.5-6 cm in diameter) localised to the region of the head of the pancreas were studied.
  • All presented with obstructive jaundice which was relieved by biliary stenting prior to further treatment.
  • Three days later, light was delivered to the cancer percutaneously using fibres positioned under computerised tomographic guidance.
  • Three had subsequent chemotherapy.
  • RESULTS: All patients had substantial tumour necrosis on scans after treatment.
  • Eleven had a Karnofsky performance status of 100 prior to treatment.
  • Two patients with tumour involving the gastroduodenal artery had significant gastrointestinal bleeds (controlled without surgery).
  • Three patients developed duodenal obstruction during follow up that may have been related to treatment.
  • There was no treatment related mortality.
  • The median survival time after photodynamic therapy was 9.5 months (range 4-30).
  • Seven of 16 patients (44%) were alive one year after photodynamic therapy.
  • CONCLUSIONS: Photodynamic therapy can produce necrosis in pancreatic cancers with an acceptable morbidity although care is required for tumours invading the duodenal wall or involving the gastroduodenal artery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. Photochemotherapy / methods
  • [MeSH-minor] Aged. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1988 May;38(1):4-9 [2967404.001]
  • [Cites] Photochem Photobiol. 1987 Nov;46(5):795-800 [3441502.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):1-12 [2121925.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1108-15 [1764374.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):786-90 [1393474.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):248-54 [8054272.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1185-9 [7953356.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):337-44 [7835574.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Laryngoscope. 1995 Aug;105(8 Pt 1):867-71 [7630302.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1473-9 [8664115.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Cancer. 1997;76(6):713-8 [9310235.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1370-6 [9361591.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):1-7 [9468416.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Gut. 1998 Sep;43(3):345-9 [9863479.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] BJU Int. 1999 Nov;84(7):821-6 [10532979.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):17-31 [10638554.001]
  • [Cites] J Natl Cancer Inst. 1988 Jul 20;80(10):751-5 [2898536.001]
  • (PMID = 11889078.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1773165
  •  go-up   go-down


50. Nakagawa Y, Todoroki T, Morishita Y, Mori K, Nakahaashi C, Ohkohchi N, Matsumoto H: A long-term survivor after pancreaticoduodenectomy for metastatic undifferentiated carcinoma of an unknown primary. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1557-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 53-year-old female had complaints of intermittent high fever and a large palpable epigastric tumor.
  • A CT scan revealed that a very large well-circumscribed solid mass occupied the posterior portion of the head of the pancreas and extended to the hepatic hilum.
  • The serum carcinoembryonic antigen (CEA), CA-125 and carbohydrate antigen 19-9 (CA19-9) levels were within the normal ranges.
  • Histologically, the tumor showed solid or diffuse proliferation of pleomorphic cells, and the immunohistochemistry suggested a metastatic tumor originating from the epithelium, the primary site was not determined despite of full review of all metastatic lesions to pancreas handled surgically and non-surgically.
  • Adjuvant oral chemotherapy of UFT and cimetidine continued for 3 years and the patient alive and healthy 6 years after surgery.
  • Even for dismal prognostic undifferentiated CUP, radical surgery would be an effective component of multidisciplinary treatment, provided that the tumor is respectable without elevation of serum tumor markers and adjuvant chemotherapy is able to appropriately supplement.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Survivors. Tegafur / therapeutic use. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102342.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


51. Sváb J, Pesková M, Krusina L, Skrha J, Sindelka G: [Personal experience with surgical treatment of insulinoma]. Rozhl Chir; 2001 Feb;80(2):77-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Personal experience with surgical treatment of insulinoma].
  • In 42 a localized tumour was removed, in one diffuse adenomatosis was involved.
  • In three of the operated patients a malignant, enddocrinologically active insulinoma was confirmed.
  • For localization of the tumour before operation US, CT and angiographic examinations were used.
  • The tumour was found in the head of the pancreas in 13 patients (31%), in the body of the pancreas in 14 (33%) and in the tail of the pancreas in 15 (36%).
  • A total of 17 patients (8 after surgery and 9 without surgery) were successfully treated with diazoxide, in 9 patients this treatment is still administered.
  • Pharmacological treatment is therefore justified only in the first group of patients.
  • Our experience indicates that a surgical approach is suitable when the diagnosis is unequivocal, even when there is a negative topographic finding of imaging methods as in 33% of the operated patients the insulinoma was detected only on operation.
  • [MeSH-major] Insulinoma / surgery. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881920.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


52. Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, Gibbs JF: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol; 2002 Nov;9(9):855-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.
  • BACKGROUND: Neuroendocrine tumors of the pancreas are rare tumors.
  • METHODS: Fifty patients with a diagnosis of neuroendocrine tumors of the pancreas were retrospectively evaluated.
  • The following factors were evaluated for disease-specific mortality: age, sex, primary tumor location, functional status, type of primary tumor treatment, presence or absence of liver metastases, timing of liver metastases occurrence, and type of liver metastases treatment.
  • Aggressive treatment of the liver metastases included surgery, chemoembolization, or intrahepatic arterial infusion chemotherapy.
  • RESULTS: Twenty-three patients (47%) had tumor located in the head of the pancreas, and 29 patients (58%) had nonfunctioning tumor.
  • Factors that had a significant favorable effect on survival included curative resection of the primary tumor, metachronous liver metastases, absence of liver metastases, and aggressive treatment of the liver metastases.
  • CONCLUSIONS: Definitive surgical resection of the primary tumor, absence of liver metastases, metachronous liver metastases, and aggressive treatment of the liver metastases were predictors of long-term survival in patients with neuroendocrine tumors of the pancreas.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12417506.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Demirkan B, Unek IT, Eriksson B, Akarsu M, Durak H, Sağol O, Obuz F, Binicier C, Füzün M, Alakavuklar M: A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report. Turk J Gastroenterol; 2009 Sep;20(3):214-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
  • Pancreatic neuroendocrine tumors constitute about 2% of all gastrointestinal neoplasms.
  • Approximately half of the pancreatic euroendocrine tumors are nonfunctional.
  • Due to lack of specific symptoms, most patients with nonfunctional pancreatic neuroendocrine tumors present with locally advanced or metastatic disease.
  • Colon carcinoma ranks third in frequency among primary sites of cancer in both men and women in western countries.
  • Presence of a metachronous colon adenocarcinoma in a patient with nonfunctional pancreatic neuroendocrine tumor has not been reported before.
  • We present a patient who had an asymptomatic mass in the head of the pancreas, detected by ultrasonography in 1996.
  • In 2002, after the diagnosis of an unresectable, nonfunctional pancreatic neuroendocrine tumor, interferon alpha- 2b and octreotide were started.
  • A year after biological treatment, he refused further treatment.
  • In 2004, during the evaluation of dissemination of the asymptomatic disease, positron emission tomography revealed a high uptake by the descending colon despite the failure of other imaging methods.
  • After surgery for operable colon carcinoma, the patient received chemotherapy and biological therapy for both tumors.
  • Since 2005, he has been doing well without any further treatment thus far.
  • In conclusion, computerized tomography/magnetic resonance imaging and octreotide scintigraphy may be insufficient to show disseminated disease and asymptomatic second primary malignancies.
  • Therefore, positron emission tomography is a valuable promising option for the evaluation of gastroenteropancreatic neuroendocrine tumors and concomitant or metachronous malignancies.
  • Lifelong follow-up by a multidisciplinary oncology team is needed so that a long-term survival can be achieved with integrated multimodal systemic treatment approaches.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821205.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


54. Chan WH, Cheow PC, Chung AY, Ong HS, Koong HN, Wong WK: Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results. ANZ J Surg; 2008 Sep;78(9):767-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results.
  • BACKGROUND: Pancreaticoduodenectomy (PD) for locally advanced stomach cancer involving duodenum or/and pancreatic head was controversial and rarely carried out.
  • METHODS: A review of prospective database from January 2003 to December 2006 of patients who had locally advanced stomach cancer involving duodenum or/and head of pancreas that precluded curative subtotal gastrectomy who underwent diagnostic laparoscopy or exploratory laparotomy to exclude peritoneal metastatic disease.
  • Patients were advised to undergo neoadjuvant chemotherapy before PD.
  • Only four patients had neoadjuvant chemotherapy before PD.
  • The median operative time was 8 h (range 6-9 h).
  • Three patients developed controlled pancreatic leaks and fistulas that were successfully treated with conservative measures.
  • Patients who received neoadjuvant chemotherapy seemed to have better survival rate (P = 0.039).
  • CONCLUSION: Our initial experience has shown that with careful and stringent patients selection, PD for locally advanced stomach cancer can be carried out with acceptable morbidity and mortality.
  • Early results for patients who received neoadjuvant chemotherapy showed trend towards prolonged survival.
  • [MeSH-major] Duodenal Neoplasms / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Feasibility Studies. Humans. Neoplasm Invasiveness. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844905.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


55. Bauditz J, Rudolph B, Wermke W: Osteoclast-like giant cell tumors of the pancreas and liver. World J Gastroenterol; 2006 Dec 28;12(48):7878-83
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-like giant cell tumors of the pancreas and liver.
  • Osteoclast-like giant cell tumors (OGCT) are rare abdominal tumors, which mainly occur in the pancreas.
  • Here we report on two cases of osteoclast-like giant cell tumors, one located within the pancreas, the other within the liver, in which OGCTs are extremely rare.
  • Both patients were investigated by contrast sonography, which demonstrated a complex, partly cystic and strongly vascularized tumor within the head of the pancreas in the first patient and a large, hypervascularized neoplasm with calcifications within the liver in the second patient.
  • With a combination of surgical resection, radiofrequency ablation and chemotherapy, the patient's survival is currently more than 15 mo, making him the longest survivor with an OGCT of the liver to date.
  • [MeSH-major] Giant Cell Tumors / pathology. Liver Neoplasms / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):516-20 [15953882.001]
  • [Cites] Int J Clin Oncol. 2002 Dec;7(6):376-80 [12494256.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):761-6 [15209622.001]
  • [Cites] Cancer. 1968 Aug;22(2):333-44 [5660199.001]
  • [Cites] Cancer. 1977 Mar;39(3):1181-9 [912652.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):771-9 [6994872.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):837-42 [6331629.001]
  • [Cites] Tumori. 1985 Dec 31;71(6):615-20 [3001983.001]
  • [Cites] Acta Pathol Jpn. 1987 Aug;37(8):1327-35 [3673575.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):111-6 [2153001.001]
  • [Cites] Cancer. 1992 May 15;69(10):2444-8 [1314689.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Histopathology. 1993 Aug;23(2):187-9 [8406392.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1055-7 [8281385.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):334-5 [8634058.001]
  • [Cites] Pathol Int. 1997 May;47(5):318-24 [9143028.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):215-8 [9334844.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1247-54 [9777987.001]
  • [Cites] Pancreas. 1999 Apr;18(3):308-15 [10206490.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):207-14 [15694816.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Pancreatology. 2005;5(2-3):279-84 [15849490.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):77-80 [11232955.001]
  • (PMID = 17203538.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087560
  •  go-up   go-down


56. Kuttikat A, Keat A, Hughes R, Hakim A, Chakravarty K: A case of polymyalgia rheumatica, microscopic polyangiitis, and B-cell lymphoma. Nat Clin Pract Rheumatol; 2006 Dec;2(12):686-90; quiz 1p following 691
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of development of jaundice, biochemical and hematological screening, CT of the abdomen and ultrasound-guided biopsy of a pancreatic mass were conducted.
  • DIAGNOSIS: Polymyalgia rheumatica, antineutrophil-cytoplasmic-antibody-positive microscopic polyangiitis with renal involvement and B-cell lymphoma of the head of the pancreas.
  • For B-cell lymphoma of the head of the pancreas, the patient received cyclophosphamide, doxorubicin, vincristine and prednisolone once monthly.
  • [MeSH-minor] Aged. Alendronate / therapeutic use. Antibodies, Antineutrophil Cytoplasmic / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antirheumatic Agents / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Female. Humans. Immunosuppressive Agents / therapeutic use. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Microscopic polyangiitis.
  • MedlinePlus Health Information. consumer health - Polymyalgia Rheumatica.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17133254.001).
  • [ISSN] 1745-8382
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; X1J18R4W8P / Alendronate
  •  go-up   go-down


57. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • The patient, a 63-year-old man had a large tumor in the head of the pancreas, without obstructive jaundice.
  • Invasion of the tumor into the duodenum and transverse colon induced progressive anemia and ileus.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Koizumi M, Sata N, Kasahara N, Morishima K, Sasanuma H, Sakuma Y, Shimizu A, Hyodo M, Yasuda Y: Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports. JOP; 2010;11(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
  • CONTEXT: Although surgical resection is the only curative therapeutic option for recurrent or metachronous pancreatic carcinomas, most such cancers are beyond surgical curability.
  • We herein report on two rare cases of remnant pancreatectomy used to treat recurrent or metachronous pancreatic carcinomas.
  • CASE REPORTS: CASE#1 A 65-year-old male developed weight loss and diabetes mellitus 83 months after a pylorus-preserving pancreaticoduodenectomy followed by two years of adjuvant chemotherapy (5-fluorouracil plus leucovorin plus mitomycin C) for a pancreatic carcinoma in the head of the pancreas (stage IA).
  • An abdominal CT scan revealed a 3 cm tumor in the remnant pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant distal pancreatectomy was performed and a pancreatic carcinoma similar in profile to the primary lesion (stage IIB) was confirmed pathologically.
  • CASE#2 A 67-year-old male showed increased CA 19-9 levels 25 months after a distal pancreatectomy for a pancreatic carcinoma in the body of the pancreas (stage IA).
  • An abdominal CT scan revealed a cystic lesion in the cut end of the pancreas which appeared as a 'hot' nodule on FDG-PET.
  • A remnant proximal pancreatectomy with duodenectomy was performed and a metachronous pancreatic carcinoma (stage III) was confirmed pathologically.
  • CONCLUSION: Remnant pancreatectomy can be considered a treatment option for recurrent or metachronous pancreatic carcinomas.
  • FDG-PET can play a key role in detecting remnant pancreatic carcinomas.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18. Humans. Male. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Hackert T, Büchler MW, Werner J: Surgical options in the management of pancreatic cancer. Minerva Chir; 2009 Oct;64(5):465-76
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical options in the management of pancreatic cancer.
  • Management of pancreatic cancer is an interdisciplinary challenge as this tumor entity is still characterized by a poor prognosis and an overall long-term survival of only 1-5%.
  • From the oncological dimension, pancreatic cancer represents the fourth leading cause of cancer related mortality in the Western world with more than 100000 deaths in Europe and the USA per year.
  • A major problem is the early detection since 80-90% of pancreatic cancers are locally or systemically advanced at the time of diagnosis.
  • Yet, surgical therapy has to be embedded in an oncological concept of adjuvant treatment as postoperative chemotherapy is a key factor to further improve patient survival.
  • Numerous ongoing studies on new therapeutic agents like antibodies, antimetabolites and supportive agents reflect the current scientific and clinical struggle to achieve better outcome of pancreatic cancer patients in the future on the basis of initial tumor resection or if this is not possible as a palliative treatment.
  • Standard resections include partial pancreatico-duodenectomy with distal gastric resection or recently accepted as the preferable procedure preservation of the pylorus for tumors in the head of the pancreas, distal pancreatectomy for tumors of the corpus and tail as well as total pancreatectomy for more extended tumors or intraductal papillary mucinous neoplasias if necessary.
  • Today, standardization of surgical procedures and centralization of pancreatic surgery in high volume institutions guarantees best patient care and mortality rates below 5%.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Pancreaticoduodenectomy. Postoperative Complications / etiology. Postoperative Complications / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859037.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, Oka M, Kinoshita H, Kimura W, Shimada H, Tanaka M, Nakao A, Hirata K, Yasuda H: The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg; 2009;16(4):485-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
  • BACKGROUND: Pancreatic carcinoma causes more than 20,000 deaths every year in Japan.
  • The role of (neo-) adjuvant chemotherapy for pancreatic carcinoma is still controversial.
  • METHODS: At the 34th Annual Meeting of the Japanese Society of Pancreatic Surgery in 2007, questionnaires were distributed regarding the use of (neo-) adjuvant chemo(radio)therapy for pancreatic carcinoma between 2001 and 2005.
  • There were a total of 1,846 cases of resected pancreatic carcinoma between 2001 and 2005.
  • The lesion was located in the head of the pancreas in 1,204 cases (71.7%), in the body in 353 cases (21.0%), and in the tail in 111 cases (6.6%).
  • Adjuvant chemotherapy (usually involving gemcitabine) was used in 66.0% of cases.
  • The use of adjuvant chemotherapy was found to improve the overall survival rate.
  • Interestingly, adjuvant chemotherapy only improved survival in late-stage (UICC stages IIB, III, and IV) but not early stage (IA, IB, and IIA) patients.
  • Survival was treatment duration-dependent, with patients who received more than 12 months of therapy having a 3-year survival rate of 51.2%.
  • CONCLUSION: This high volume retrospective data indicated the promising effect of gemcitabine-based adjuvant chemotherapy and the rational duration of adjuvant chemotherapy should be determined in the future prospective studies.
  • [MeSH-major] Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Health Surveys. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333537.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


61. Hopt UT: [Treatment of carcinoma of the pancreatic head]. Zentralbl Chir; 2006 Apr;131(2):115-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of carcinoma of the pancreatic head].
  • [Transliterated title] Therapie des Pankreaskopfkarzinoms.
  • For patients with carcinoma in the head of the pancreas surgical resection remains the only chance of cure.
  • Only a small percentage of all patients suffering from pancreas carcinoma are good candidates for an operative therapy.
  • The most frequent contraindications are metastases in the liver or the peritoneum or a locally too advanced tumor.
  • The extent of surgical resection necessary in patients with pancreas carcinoma is still in discussion.
  • A substantial improvement of long term- survival can only be expected from new multimodal therapeutic strategies.
  • Adjuvant chemotherapy should strongly be recommended after resection of a pancreas carcinoma.
  • Neoadjuvant therapy on the other hand is still an experimental procedure and under evaluation in ongoing prospective randomized studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Humans. Lymph Node Excision / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612777.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


62. Pietsch JB, Shankar S, Ford C, Johnson JE: Obstructive jaundice secondary to lymphoma in childhood. J Pediatr Surg; 2001 Dec;36(12):1792-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports in adults and children suggest that these lymphomas are associated with a poor prognosis.
  • Abdominal ultrasound scan and computed tomography (CT) scans were helpful in defining the anatomy of the obstruction.
  • In the cases of involvement of the porta hepatis, the diagnosis was made by biopsy.
  • In one child a mass was in the head of the pancreas, and evaluation of frozen section biopsy results were not diagnostic for lymphoma, and a major resection was performed.
  • All the lymphomas were of nonHodgkin's B-cell type and one was a Burkitt's lymphoma.
  • All responded promptly to chemotherapy.
  • One child had a testicular relapse and currently is receiving additional therapy.
  • Biopsy alone without resection or biliary drainage is recommended surgical therapy.
  • Long-term survival rate in children with this disorder appears to be more promising than previously reported.
  • [MeSH-major] Cholestasis / etiology. Lymphoma / complications. Pancreatic Neoplasms / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Female. Humans. Male. Prognosis. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11733908.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Minchom A, Chan S, Melia W, Shah R: An unusual case of pancreatic cancer with leptomeningeal infiltration. J Gastrointest Cancer; 2010 Jun;41(2):107-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of pancreatic cancer with leptomeningeal infiltration.
  • INTRODUCTION: Pancreatic cancer is a common malignancy and often presents at an advanced stage.
  • We aim to describe an unusual case of leptomeningeal involvement from pancreatic cancer.
  • CASE REPORT: A 59-year-old man presented with a several-year history of abdominal pain, weight loss and anaemia, which had been extensively investigated.
  • CT scan of the abdomen showed subtle narrowing of the common bile duct and pancreatic ducts.
  • Endoscopic ultrasound showed a 5-cm lesion in the head of the pancreas with adenocarcinoma cells on fine needle aspiration.
  • He started on a weekly regimen of intrathecal combination chemotherapy of hydrocortisone 50 mg, methotrexate 12.5 mg and cytarabine 50 mg.
  • His clinical condition continued to deteriorate, cytotoxic therapy was withdrawn after 2 weeks and he died the following month.
  • DISCUSSION: This case represents the unusual presentation of advanced leptomeningeal carcinomatosis in a locally early stage pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Carcinomatosis / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Humans. Hydrocortisone / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2006 Mar 14;66(5):783; author reply 783 [16534138.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • [Cites] Neurochirurgia (Stuttg). 1980 Jan;23(1):13-7 [7352044.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Dec;35(13):2413-6 [19098414.001]
  • [Cites] Acta Neurol (Napoli). 1975 Jul-Aug;30(4):359-67 [1229842.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5 [10917346.001]
  • [Cites] Cancer Treat Res. 2005;125:147-58 [16211888.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 20069465.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Albu A, Zirnea A, Georgescu O, Terzea D, Jinga D, Fica S: Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature. J Med Life; 2008 Apr-Jun;1(2):210-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature.
  • Malignant insulinomas are rare tumors (10% of insulinomas) that often present as mnulticentric macro nodules with multiple liver metastases before diagnosis.
  • We report the case of a 55 year old female with a medical history of severe hypoglycemic attacks for two months.
  • Blood tests showed a decreased value of glycemia (30 mg/dl) associated with increased insulin level (l6 microU/ml) and an increased glycemia/insulinemia ratio of 1.87 supporting the diagnosis of insulinoma.
  • Abdominal CT showed a 1.5 cm mass localized in the head of the pancreas with disseminated hepatic tumors, confirmed as neuroendocrine metastases by biopsy (which proved the presence of a malignant insulinoma).
  • Primary hyperparathyroidism was diagnosed based on mild elevation of calcium (10.4 mg/dl) associated with a high level of PTH (71.2 pg/ml).
  • The coexistence of the two endocrinopathies suggested the presence of type 1 multiple endocrine neoplasia (MEN 1).
  • Somatostatin analog therapy was started with symptomatic control in the beginning, but rapid loss of beneficial effect.
  • Finally, systemic chemotherapy with doxorubicin was administered, but the disease was progressive and after three months we decided to stop it.
  • [MeSH-major] Hyperparathyroidism, Primary / complications. Insulinoma / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology


65. Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G: Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain. Onkologie; 2009 Mar;32(3):119-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Only few cases of pancreatic involvement of multiple myeloma (MM) have been reported in the medical literature.
  • PATIENTS AND METHODS: We here report a case of devastating extramedullary relapse of IgA/lambdaMM (stage IA) treated at diagnosis with a dexamethasone, adriamycin, vincristine (DAV) regimen followed by high-dose therapy and autologous stem cell transplantation (ASCT), achieving a partial remission.
  • After 6 years of stable disease, the patient presented symptoms of obstructive jaundice determined by a large mass of the head of the pancreas.
  • An ultrasound-guided fine-needle aspiration cytology of the pancreatic mass revealed the presence of myeloma plasma cells.
  • RESULTS: We observed a progression of disease despite an aggressive treatment with high-dose cyclophosphamide.
  • CONCLUSIONS: Our case shows that extramedullary relapses of MM after ASCT are very resistant to conventional chemotherapy.
  • The role of new drugs and the optimal treatment strategy in these cases remain to be defined.
  • [MeSH-major] Abdominal Pain / prevention & control. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Immunoglobulin lambda-Chains / analysis. Jaundice, Obstructive / prevention & control. Multiple Myeloma / drug therapy. Neoplasm Recurrence, Local / prevention & control. Pancreatic Neoplasms / drug therapy


66. Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer; 2009 Feb 25;9:66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.
  • BACKGROUND: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage.
  • However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome.
  • This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I(131) in pancreatic cancer (ISRCTN 16857581).
  • METHODS: Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route.
  • One patient was still alive at the time of this analysis.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoembryonic Antigen / administration & dosage. Immunotoxins / administration & dosage. Iodine Radioisotopes / administration & dosage. Pancreatic Neoplasms / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Neoplasm / biosynthesis. Antibodies, Neoplasm / immunology. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Middle Aged. Radiography. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s [10541369.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):406-14 [10690517.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):45-57 [11135320.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6851-9 [11559561.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1373-81 [11877768.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Clin Colorectal Cancer. 2002 May;2(1):31-42 [12453334.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69 [14653825.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):618-26 [14991585.001]
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):11-22 [794493.001]
  • [Cites] Ann N Y Acad Sci. 1983;417:75-85 [6200051.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] J Surg Oncol. 1991 Jul;47(3):148-54 [2072697.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):858-70 [9189130.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):34-42 [9443735.001]
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9 [9756018.001]
  • [Cites] Hybridoma. 1999 Apr;18(2):183-91 [10380018.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Ann Nucl Med. 2005 Jul;19(5):355-65 [16164191.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):196-9 [16455623.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):247-55 [16455630.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):823-34 [16380412.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Curr Drug Discov Technol. 2006 Dec;3(4):231-43 [17430101.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 19243606.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN16857581
  • [Grant] United Kingdom / Medical Research Council / / G9900432; United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2656541
  •  go-up   go-down


67. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • Specific information regarding intraductal papillary mucinous neoplasm (IPMN) recurrence is limited because most series are small and the follow-up interval is short.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • The patient did not receive postoperative chemotherapy and was monitored with transaxial imaging at regular intervals.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country.
  • Risk factors include smoking, certain familial cancer syndromes, and familial chronic pancreatitis.
  • The link between risk of pancreatic cancer and other factors (e.g., diabetes, obesity) is less clear.
  • Most patients present with obstructive jaundice caused by compression of the bile duct in the head of the pancreas.
  • Epigastric or back pain, vague abdominal symptoms, and weight loss also are characteristic of pancreatic cancer.
  • More than one half of cases have distant metastasis at diagnosis.
  • Computed tomography is the most useful diagnostic and staging tool.
  • The majority of tumors are not surgically resectable because of metastasis and invasion of the major vessels posterior to the pancreas.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Adjuvant fluorouracil-based chemotherapy may prolong survival.
  • For nonresectable tumors, chemotherapy with gemcitabine prolongs survival.
  • Radiation combined with chemotherapy has slowed progression in locally advanced cancers.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


69. Rykowski JJ, Hilgier M: Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. Anesthesiology; 2000 Feb;92(2):347-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief.
  • BACKGROUND: Neurolytic celiac plexus block (NCPB) is an effective way of treating severe pain in some patients with pancreatic malignancy.
  • However, there are no studies to date that evaluate the effectiveness of NCPB related to the site of primary pancreas cancer.
  • The aim of the study was to assess the effectiveness of NCPB in pancreatic cancer pain, depending on the location of the pancreatic tumor.
  • METHODS: The prospective study was conducted in 50 consecutive patients diagnosed with pancreatic cancer.
  • The patients were categorized into two different groups depending on tumor localization: group 1: patients with the cancer of the head of the pancreas and group 2: patients with the cancer of the body and tail of the pancreas.
  • Those patients were scheduled for repeated retrocrural neurolysis during computed tomography control.
  • Computed tomography showed massive growth of the tumor around the celiac axis with metastases.
  • After repeated neurolysis, pain relief clinically still was not satisfactory, necessitating additional opioid treatment.
  • CONCLUSION: In this study, unilateral transcrural celiac plexus neurolysis has been shown to provide effective pain relief in 74% of patients with pancreatic cancer pain.
  • Neurolysis was more effective in cases with tumor involving the head of the pancreas.
  • In the cases with advanced tumor proliferation, regardless of the technique used, the analgesic effects of NCPB were not satisfactory.
  • [MeSH-major] Celiac Plexus. Nerve Block. Pain, Intractable / drug therapy. Pancreatic Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anesthetics, Local. Bupivacaine. Female. Humans. Male. Middle Aged. Pain Measurement. Prospective Studies. Survival. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10691219.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local; Y8335394RO / Bupivacaine
  •  go-up   go-down


70. Dumonceau JM, Vonlaufen A: Pancreatic endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy; 2007 Feb;39(2):124-30
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endoscopic retrograde cholangiopancreatography (ERCP).
  • We review developments in five areas of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) and management of pancreatic tumors during the period September 2005-August 2006.
  • First, in the management of painful chronic pancreatitis, the use of multiple plastic stents for aggressive dilation of strictures located in the head of the pancreas has been put forward to resolve two significant issues associated with current techniques, i. e., the requirement for numerous ERCPs for stent exchange and the high relapse rate after stent removal.
  • We then discuss the identification of protective factors against post-ERCP pancreatitis following pancreatic sphincterotomy.
  • Next, bearing in mind the prospect of increasing use of neoadjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma, new evidence supporting the systematic use of self-expandable metal biliary stents before cancer staging is presented and critically considered.
  • Finally two centers with a high volume of cases have reported their experience with the drainage of pancreatic fluid collections with or without endosonography (EUS) guidance.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Pancreatitis / therapy. Stents
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chronic Disease. Drainage / methods. Humans. Pancreatic Ducts / pathology. Risk Factors. Sphincterotomy, Endoscopic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327971.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 23
  •  go-up   go-down


71. Matsuda M, Watanabe G, Mine S, Hashimoto M: [Fatal liver failure associated with gemcitabine hydrochloride therapy]. Gan To Kagaku Ryoho; 2008 Jan;35(1):157-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal liver failure associated with gemcitabine hydrochloride therapy].
  • We report a case of fatal liver failure associated with gemcitabine hydrochloride(GEM)therapy.
  • In February 2005, a 79-year-old man with a history of diabetes mellitus and chronic hepatitis C was admitted for the treatment of carcinoma of the head of the pancreas.
  • Abdominal CT revealed no distant metastases, but the tumor had invaded the portal vein.
  • Surgery was too risky because of his age and condition, so radiation therapy(60 Gy)was combined with GEM(800 mg on days 1 and 8 of a 3-week cycle).
  • The treatment was well tolerated.
  • Autopsy revealed extensive centrilobular necrosis of the liver and confirmed a diagnosis of drug-induced liver failure.
  • Careful monitoring is necessary during GEM therapy, especially in patients with liver dysfunction.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Liver Failure / chemically induced. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Male. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


72. Défachelles AS, Martin De Lassalle E, Boutard P, Nelken B, Schneider P, Patte C: Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients. Med Pediatr Oncol; 2001 Jul;37(1):47-52
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients.
  • BACKGROUND: To analyze the clinical course of pancreatoblastoma in children and to propose management and therapy.
  • PROCEDURE: Retrospective review of seven cases of pancreatoblastoma treated in France over a 20-year period and literature review.
  • The tumor was well encapsulated in one patient and had direct extension to adjacent tissues in two others.
  • The tumor arose in the head of the pancreas in three children, in the tail and body in two and in the tail and in the body, one each.
  • Five tumor resections were performed, one initially and 4 after neoadjuvant chemotherapy, and cisplatin plus doxorubicin seemed effective.
  • In all, four children are disease free with a median follow-up of 50 months ( range, 5--120 months) : one had a complete removal of tumor at diagnosis and no further treatment, three had unresectable tumor at diagnosis and received neoadjuvant chemotherapy with cisplatin and doxorubicin.
  • CONCLUSIONS: Pancreatoblastoma is a curable tumor.
  • Examination of serum AFP levels may be useful for diagnosis and to follow the course of the disease.
  • Complete resection is the treatment of choice.
  • However, tumor is often unresectable at diagnosis and preoperative chemotherapy is needed to reduce tumor volume.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatectomy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Retrospective Studies. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11466723.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 48
  •  go-up   go-down


73. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E: Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. J Surg Oncol; 2001 Apr;76(4):289-96
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature.
  • BACKGROUND: Solid-pseudopapillary tumor of the pancreas (SPT) is an exceptionally rare neoplasm in children.
  • It is of low malignant potential and occurs most frequently in young females.
  • PATIENTS AND METHODS: A cumulative review of the tumor's clinicopathological characteristics from the world's literature is presented.
  • Two tumors were located in the tail, one in the body and tail and one in the head of the pancreas (diameter: 7--15 cm).
  • Surgical procedures included three distal pancreatectomies and one partial duodenopancreatectomy (Whipple procedure).
  • Chemotherapy was initiated for this patient.
  • CONCLUSIONS: SPT is a rare differential diagnosis of a pancreatic mass in children.
  • It is mandatory to establish this diagnosis since complete surgical removal of the tumor even in case of metastases or local invasion offers an excellent prognosis.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11320522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


74. Barreda Bolaños F, Landeo Aliaga I, Pando Huarcaya S, Bayro Peñaloza F: [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography]. Rev Gastroenterol Peru; 2008 Apr-Jun;28(2):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography].
  • [Transliterated title] Adenocarcinoma de páncreas en paciente joven diagnosticado por ultrasonografía endoscópica.
  • The Pancreatic adenocarcinoma appears generally in patients with more than 60 years old.
  • The tomografic image showed a mass located in the head of the pancreas with hepatic and ganglionar metastases.
  • It was evaluated by means of endoscopic ultrasonography (USE) and performed a directed fine needle puncture aspiration (PAAF), that obtained a bad differentiated adenocarcinoma from the pancreas.
  • An endoscopic biliary drainage by PCRE was realized later and treatment with chemotherapy started.
  • We present the case by the unusual occurrence in the related age group and by the importance of the puncture guided by endoscopic ultrasonography in the diagnosis and handling of this pathology [corrected]
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):293
  • (PMID = 18641779.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


75. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinoma of the stomach is an uncommon tumor, usually associated with highly malignant biological behavior and extremely poor prognosis.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • During the operation, an obviously swollen lymph node on the anterior surface of the head of the pancreas 4.0 x 3.5 cm in size was found growing into the parenchyma of the pancreas head and could not be separated from the pancreas, and the swollen lymph node along the superior mesenteric vein was also hard and suspected to be a metastatic node.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor to be neuroendocrine carcinoma.
  • The obvious swollen lymph node on the anterior surface of the head of the pancreas and the swollen lymph node along the superior mesenteric vein were also identified as metastatic lymph nodes.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


76. Padidela R, Kapoor RR, Moyo Y, Gilbert C, Flanagan SE, Ellard S, Hussain K: Focal congenital hyperinsulinism in a patient with septo-optic dysplasia. Nat Rev Endocrinol; 2010 Nov;6(11):646-50
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An infant diagnosed as having hypopituitarism and on adequate hydrocortisone replacement therapy was referred to a tertiary endocrine unit at 5 weeks of age with persistent hypoglycemia that required a high rate of intravenous glucose infusion (up to 18 mg/kg•min⁻¹) to maintain euglycemia.
  • The pancreas was analyzed by fluorine-18-L-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET scan.
  • Genetic analyses were performed on the peripheral blood leukocytes, and loss of heterozygosity within the resected focal lesion of the pancreas was investigated by microsatellite analysis.
  • DIAGNOSIS: Focal form of congenital hyperinsulinism localized to the head of the pancreas, septo-optic dysplasia and pituitary hormone deficiencies.
  • MANAGEMENT: Resection of the focal lesion from the head of the pancreas and hormonal replacement therapy for hypopituitarism.
  • [MeSH-major] Congenital Hyperinsulinism / diagnosis. Septo-Optic Dysplasia / diagnosis
  • [MeSH-minor] 3-Hydroxybutyric Acid / blood. Blood Glucose / analysis. C-Peptide / blood. Glucagon. Glucose / administration & dosage. Humans. Hydrocortisone / deficiency. Hydrocortisone / therapeutic use. Hypopituitarism / complications. Hypopituitarism / diagnosis. Hypopituitarism / drug therapy. Infant. Insulin / blood. Loss of Heterozygosity. Male. Pancreas / surgery. Pituitary Hormones / deficiency. Pituitary Hormones / therapeutic use

  • Genetic Alliance. consumer health - Hyperinsulinism, focal.
  • Genetic Alliance. consumer health - Septo-optic dysplasia.
  • Genetic Alliance. consumer health - Congenital Hyperinsulinism.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842182.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin; 0 / Pituitary Hormones; 9007-92-5 / Glucagon; IY9XDZ35W2 / Glucose; TZP1275679 / 3-Hydroxybutyric Acid; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


77. Imamura H, Furukawa H, Kishimoto T, Miyazaki Y, Ohta K, Yamamoto T, Takemoto H, Fukunaga M, Ohsato H, Tatsuta M: [A case of advanced gastric cancer treated with chemo-radiotherapy as the fourth-line therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2054-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer treated with chemo-radiotherapy as the fourth-line therapy].
  • A 69-year-old female patient with type 2 advanced gastric cancer (s-T4N0M0H0Cy0P0, f-Stage IIIA) located from lower corps to antrum underwent a distal gastrectomy with D2 lymphandectomy in May 2006.
  • After surgical treatment, S-1+ docetaxel combined chemotherapy was started for pEM (+) due to direct invasion to pancreas head as the first-line chemotherapy.
  • However, the local recurrence whose diameter was 24 mm at pancreas head was detected with enhanced CT in December 2006.
  • Moreover, nevertheless CPT-11+CDDP combined chemotherapy or paclitaxel monotherapy as the second or the third-line chemotherapy, respectively, the diameter of the local recurrence enlarged to 38 mm in November 2007.
  • Therefore, chemo-radiotherapy using with S-1 and CDDP was started in December 2007 and the diameter of local recurrence was reduced to 25 mm in January 2008.
  • Chemo-radiotherapy for this gastric-cancer patient with local recurrence of multiple anti-tumor drug resistance was effective and safe.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Gastrectomy. Gastroscopy. Humans. Neoplasm Staging. Salvage Therapy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106521.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Lee MK, Jeon SW, Lee YD, Seo HE, Cho CM, Kim SG, Yoon YK: A case of primary pancreatic non-Hodgkin's lymphoma. Korean J Intern Med; 2006 Jun;21(2):123-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary pancreatic non-Hodgkin's lymphoma.
  • Primary pancreatic lymphoma is rare, comprising 0.2-4.9% of all pancreatic malignancies and less than 1% of cases of non-Hodgkin's lymphoma.
  • We report a rare presentation of diffuse large B cell lymphoma, appearing as a primary tumor of the pancreas.
  • Computed tomography of the abdomen showed a well defined mass located at the head of the pancreas.
  • A frozen section of pancreas, during laparotomy, revealed lymphoma.
  • The patient received 6 cycles of chemotherapy and is currently in complete remission.
  • This case underscores the importance of differentiating primary lymphoma from the more common adenocarcinoma of the pancreas as treatment and prognosis differ significantly.
  • Primary pancreatic lymphoma should be considered in the differential diagnosis of pancreatic tumors and an attempt to obtain a tissue diagnosis is always necessary before proceeding to radical surgery, especially on young patients.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):319-30 [10703858.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):237-47 [10962538.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):610-3 [11180896.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):259-61 [15011880.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):834-6 [9622727.001]
  • [Cites] Radiology. 1993 Apr;187(1):99-104 [8451443.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):109-12 [8877636.001]
  • [Cites] Surgery. 1998 Apr;123(4):382-90 [9551063.001]
  • [Cites] Ann Surg. 1989 Jan;209(1):25-30 [2910212.001]
  • (PMID = 16913443.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3890735
  •  go-up   go-down


79. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • The patient was diagnosed preoperatively as having extrahepatic bile duct cancer.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


80. Yano T, Ono H, Watanabe Y, Sato M: [Complete response in a case of recurrent gastric cancer treated with TS-1]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1461-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response in a case of recurrent gastric cancer treated with TS-1].
  • We report the case of 72-year-old man with recurrent gastric cancer who was successfully treated with TS-1.
  • We performed only non-curative operation because the tumor had infiltrated the pancreas head and aspiration pneumonia complications developed under the anesthetic.
  • Abdominal CT revealed local recurrence and metastasis of the paraaortic lymph node after 3 months, so we started TS-1 chemotherapy.
  • Furthermore, this therapy was continued for 3 courses without any side effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antimetabolites, Antineoplastic / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


81. Au E: Clinical update of gemcitabine in pancreas cancer. Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:469-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical update of gemcitabine in pancreas cancer.
  • Pancreatic cancer constitutes less than 2% of all cancers diagnosed in Singapore, consistent with the proportion described worldwide.
  • Most are adenocarcinomas arising from the head of the pancreas.
  • Systemic chemotherapy is used for advanced metastatic pancreatic cancer but has met with limited success.
  • In a randomised study it appears to confer statistically significant, although modest, improvement in quality of life and survival of patients with metastatic pancreas cancer.
  • Evaluation of the drug in combination chemotherapy regimens and with radiation continues.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Prognosis. Quality of Life. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895197.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 35
  •  go-up   go-down


82. Lee YJ, Jung SH, Hyun WJ, Kim SH, Lee HIe, Yang HW, Kim A, Cha SW: A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis. Gut Liver; 2009 Dec;3(4):338-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis.
  • Abdominal tuberculosis is not a rare disease, but obstructive jaundice caused by tuberculosis (tuberculous lymphadenitis, tuberculous enlargement of the head of pancreas, and/or tuberculous stricture of the biliary tree) is rare.
  • We recently experienced a case of obstructive jaundice as a result of paradoxical reaction of periportal tuberculous lymphadenopathy that was treated successfully with corticosteroid and biliary drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infection. 1997 Jul-Aug;25(4):233-9 [9266263.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):3098-100 [18494068.001]
  • [Cites] Chest. 1998 Sep;114(3):933-6 [9743188.001]
  • [Cites] J Clin Gastroenterol. 1999 Sep;29(2):161-4 [10478878.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2534-6 [10484020.001]
  • [Cites] Clin Microbiol Infect. 2000 Mar;6(3):137-41 [11168089.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9 [12461590.001]
  • [Cites] Surg Today. 2003;33(3):229-31 [12658393.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Oct;22(10):597-602 [14508660.001]
  • [Cites] Thorax. 2004 Aug;59(8):704-7 [15282393.001]
  • [Cites] Am J Gastroenterol. 1989 Apr;84(4):413-4 [2929563.001]
  • [Cites] Q J Med. 1986 Jun;59(230):599-610 [3749451.001]
  • [Cites] Lancet. 1980 Jun 7;1(8180):1208-11 [6104034.001]
  • [Cites] Lancet. 1984 Jul 28;2(8396):181-4 [6146749.001]
  • [Cites] Clin Infect Dis. 1994 Dec;19(6):1092-9 [7888539.001]
  • [Cites] Chest. 1994 Dec;106(6):1896-8 [7988222.001]
  • [Cites] Respir Med. 1996 Apr;90(4):211-4 [8736654.001]
  • [Cites] Am J Gastroenterol. 1996 Dec;91(12):2602-4 [8946995.001]
  • [Cites] Clin Infect Dis. 2005 May 1;40(9):1368-71 [15825042.001]
  • [Cites] Transpl Infect Dis. 2007 Sep;9(3):219-24 [17692068.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):779-81 [17846849.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jul;158(1):157-61 [9655723.001]
  • (PMID = 20431773.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852721
  • [Keywords] NOTNLM ; Abdominal tuberculosis / Paradoxical reaction / Periportal lymphadenitis
  •  go-up   go-down


83. Suzuki K, Miyamoto M, Miyamoto T, Hirata K: Insulinoma with early-morning abnormal behavior. Intern Med; 2007;46(7):405-8
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 65-year-old man with insulinoma who initially developed stereotypical behaviors and then progressed to more complex behaviors occurring early in the morning.
  • Insulinoma was diagnosed based on fasting blood glucose level of 15 mg/dl, high fasting immunoreactive insulin/blood glucose ratio (more than 0.3), and a tumor in the pancreas head by abdominal CT.
  • [MeSH-major] Behavioral Symptoms / etiology. Hypoglycemia / diagnosis. Hypoglycemia / psychology. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Behavior. Drug Therapy, Combination. Follow-Up Studies. Glucose / administration & dosage. Glucose Tolerance Test. Humans. Magnetic Resonance Imaging. Male. Periodicity. Prednisolone / administration & dosage. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409607.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; IY9XDZ35W2 / Glucose
  •  go-up   go-down


84. Takemura N, Kokudo N, Imamura H, Takazawa Y, Sano K, Sugawara Y, Nakagawa K, Ohtomo K, Makuuchi M: Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy. Hepatogastroenterology; 2008 Nov-Dec;55(88):1997-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eleven-year survivor of unresectable intrahepatic cholangiocarcinoma treated using long-term UFT therapy.
  • We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade.
  • In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT).
  • The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection.
  • The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head.
  • A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy.
  • The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter.
  • External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter.
  • Eleven years have now passed since the laparotomy, and the patient continues to lead a normal daily life working as a banker.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / mortality. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Progression. Humans. Male. Radiotherapy Dosage. Survivors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260466.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur
  •  go-up   go-down


85. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, Levy P, Ruszniewski P: Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol; 2006 Apr;101(4):735-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.
  • BACKGROUND: Life expectancy in patients with unresectable pancreatic cancer has improved by using new chemotherapeutic regimens.
  • AIM: To evaluate the incidence of biliary and duodenal stenoses as well as technical success and short- and long-term patency of endoscopically deployed stents in patients with unresectable pancreatic cancer.
  • PATIENTS AND METHODS: All consecutive patients with unresectable cancer of the pancreatic head seen between January 1999 and September 2003 in our center were retrospectively studied.
  • Patients with biliary and/or duodenal stenoses underwent endoscopic stent insertion as first intention therapy.
  • RESULTS: One hundred patients, median age 65 yr (32-85), with locally advanced (62%) or metastatic (38%) pancreatic cancer were studied.
  • Eighty-three percent received at least one line of chemotherapy.
  • In the 23 patients who developed both biliary and duodenal stenoses, combined stenting was successful in 91% of cases.
  • No major complication or death occurred related to endoscopic treatment.
  • CONCLUSION: Endoscopic palliative treatment of both biliary and duodenal stenoses is safe and effective in the long term, including in patients with combined obstructions.
  • [MeSH-major] Adenocarcinoma / complications. Biliary Tract. Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Duodenum. Palliative Care. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / therapy. Endoscopy. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 Apr;101(4):743-5 [16635222.001]
  • (PMID = 16635221.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Adham M, Mirza DF, Chapuis F, Mayer AD, Bramhall SR, Coldham C, Baulieux J, Buckels J: Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors. HPB (Oxford); 2006;8(6):465-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From 1989 to 2002, 45 patients (21 men, 24 women) underwent pancreatectomy for a pancreatic mass: Whipple's procedure (n=33), total pancreatectomy (n=10) or left splenopancreatectomy (n=2), along with a vascular resection, i.e. venous (n=39), arterial (n=1) or venous + arterial (n=5).
  • Reoperations were performed for portal vein thrombosis (n=1), pancreatic leak (n=1), gastric outlet syndrome (n=1) and gastrointestinal bleeding (n=1).
  • In all, 43 patients had cancer on pathology examination, with retropancreatic invasion in 72% and lymph node extension in 62.8%.
  • A multivariate analysis of prognostic variables identified tumour location (other than head of pancreas), neoadjuvant chemotherapy and advanced disease stage as adverse factors for DFS.
  • Tumour localization, tumour stage, neoadjuvant treatment and tumour recurrence are explanatory variables of survival.
  • Tumour localization, tumour stage and neoadjuvant treatment were explanatory variables for DFS.
  • However, the type and extent of vascular resections as well as vessel wall invasion does not affect survival and DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):188-99 [1727753.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] N Y State J Med. 1971 Feb 1;71(3):366-8 [4323555.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1596-600 [16201124.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1056-61 [16006800.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):130-4 [15730937.001]
  • [Cites] Ann Surg. 1992 Mar;215(3):231-6 [1543394.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):110-3 [15004752.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):263-6 [12630036.001]
  • [Cites] Surg Today. 2002;32(7):598-601 [12111516.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):258-62 [11941970.001]
  • [Cites] J Am Coll Surg. 2001 Nov;193(5):576-8 [11708518.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2609-15 [11569683.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):492-7 [10228849.001]
  • [Cites] Surg Today. 1999;29(1):16-22 [9934826.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] AJR Am J Roentgenol. 1997 Apr;168(4):971-7 [9124153.001]
  • [Cites] J Surg Res. 1996 Jul 15;64(1):32-4 [8806470.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):202-6 [8661548.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Jpn J Surg. 1983 Sep;13(5):385-94 [6366309.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] Br J Surg. 1994 Nov;81(11):1642-6 [7827892.001]
  • (PMID = 18333103.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020757
  •  go-up   go-down


87. Matsumoto T, Fujiwara Y, Yamamoto N, Hayashi C, Koishi K, Kojima S, Tanaka J, Kobayashi M, Yamamura T, Miwa H, Tomita N, Sasako M: [Gastrojejunostomy for irresectable gastric cancer with pyloric stenosis-new role of surgery in the era of S-1]. Gan To Kagaku Ryoho; 2009 Apr;36(4):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrojejunostomy for irresectable gastric cancer with pyloric stenosis-new role of surgery in the era of S-1].
  • We report a patient with an advanced gastric cancer complicated by pyloric stenosis who was effectively treated by S-1 mono-therapy after gastrojejunostomy.
  • Gastric roentgenography and upper gastrointestinal endoscopy showed gastric cancer(Borrmann Type 3) with pyloric stenosis.
  • He underwent laparotomy, which revealed a T4 tumor invading the pancreas head, but neither liver nor peritoneal metastasis.
  • After the operation, chemotherapy of S-1(120 mg/day, day 1-21)+cisplatin(100 mg/day, day 8)was administered.
  • After 2 courses, level of tumor marker decreased remarkably and abdominal enhanced computed tomography showed a significant size reduction of lymph nodes and that direct invasion to the pancreas was not clear any more.
  • After 4 courses of S-1(120 mg/day, day 1 approximately 28)mono-therapy as adjuvant chemotherapy, bone metastasis was confirmed by scintigram.
  • Then methotrexate+5-FU, irinotecan+cisplatin and cisplatin+paclitaxel were chosen as second-, third-and fourth-line chemotherapy, which were not effective for long.
  • In the past, gastrojejunostomy was regarded as useful palliative treatment for those with gastric outlet stenosis to ameliorate the QOL.
  • As S-1 is taking major role in the chemotherapy for advanced gastric cancer recently, usefulness of bypass surgery for such patients is highlighted even for longer survival time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Bypass. Oxonic Acid / therapeutic use. Pyloric Stenosis / drug therapy. Pyloric Stenosis / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Drug Combinations. Fatal Outcome. Gastroscopy. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381039.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


88. Ito R, Shiba H, Okamoto T, Fujioka S, Gocho T, Yanaga K: Groove Pancreatitis with Several Cystic Lesions around the Pancreatic Head Treated Conservatively: Report of a Case. Case Rep Gastroenterol; 2008 Sep;2(3):405-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Groove Pancreatitis with Several Cystic Lesions around the Pancreatic Head Treated Conservatively: Report of a Case.
  • Enhanced abdominal computed tomography revealed inflammatory change of the pancreatic groove and focal wall thickening of the second portion of the duodenum with several cystic lesions around the head of the pancreas.
  • We diagnosed atypical type of groove pancreatitis.
  • The patient made a satisfactory recovery by conservative medication treatment for acute on chronic pancreatitis and cystic lesions disappeared in parallel with pancreatitis.
  • Groove pancreatitis is a rare form of chronic pancreatitis, and to the best of our knowledge, our patient is the first case in the English literature of groove pancreatitis with cystic lesions around the head of the pancreas, which disappeared after conservative treatment for pancreatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Presse Med. 2003 Nov 8;32(36):1705-6 [14663399.001]
  • [Cites] Hepatogastroenterology. 1982 Oct;29(5):198-208 [7173808.001]
  • [Cites] Dig Dis Sci. 2006 Jul;51(7):1294-6 [16944029.001]
  • (PMID = 21897790.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3166802
  • [Keywords] NOTNLM ; Conservative treatment / Cystic lesion / Groove pancreatitis
  •  go-up   go-down


89. Traverso LW: Pancreatic cancer: surgery alone is not sufficient. Surg Endosc; 2006 Apr;20 Suppl 2:S446-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: surgery alone is not sufficient.
  • For a patient with resected pancreatic cancer at the head of the pancreas, the goal of the medical community in the new millennium is a long-term survival rate exceeding 50% at 5 years.
  • This goal can best be achieved with the following formula: accurate staging by improved imaging that includes laparoscopy for selected patients with locally extensive disease using computed tomography; a balanced resection, not too extensive and not too limited; centralized treatment in high-volume centers, which includes not just the surgeons and hospitals, but also the chemotherapy infusion units; and use of an effective adjuvant or neoadjuvant treatment in which toxicity is associated with efficacy.
  • The ideal outcome for the surgeon is delivery of a patient who has been accurately staged to receive the most appropriate treatment in a timely fashion for an effective chemoradiotherapy protocol.
  • To do this, the surgeon should use objective benchmarks of safe pancreatic resection, which involves resecting only enough, achieving low blood loss, and achieving a minimal length of hospital stay.
  • The outcome is a patient who has optimized his or her gastrointestinal, endocrine, and exocrine functions and is ready for adjuvant treatment 6 weeks after resection.
  • [MeSH-major] Chemotherapy, Adjuvant. Pancreatectomy. Pancreatic Neoplasms / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Combined Modality Therapy. Female. Humans. Life Tables. Liver Neoplasms / secondary. Male. Neoplasm Staging. Neoplasm, Residual. Peritoneal Neoplasms / secondary. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Jun;73(6):1704-9 [12078756.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] World J Surg. 2002 Apr;26(4):487-92 [11910485.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Lancet. 1994 Aug 27;344(8922):573-8 [7914960.001]
  • [Cites] Surgery. 2005 Oct;138(4):618-28; discussion 628-30 [16269290.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg. 2004 May;187(5):604-8 [15135674.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):103-10 [12832972.001]
  • [Cites] Surg Endosc. 2005 May;19(5):638-42 [15776215.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] Ann Surg. 1992 Aug;216(2):142-5 [1354435.001]
  • (PMID = 16557419.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Ochi N, Takigawa N, Yasugi M, Ishida E, Kawamoto H, Taniguchi A, Harada D, Hayashi E, Toda H, Yanai H, Tanimoto M, Kiura K: Obstructive jaundice at the initial presentation in small-cell lung cancer. Int Med Case Rep J; 2010;3:9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice at the initial presentation in small-cell lung cancer.
  • Obstructive jaundice sometimes may develop in association with advanced small-cell lung cancer (SCLC); however, SCLC initially presenting with obstructive jaundice is rare.
  • This report presents the cases of two SCLC patients with obstructive jaundice at the initial diagnosis.
  • A 64-year-old male presented with obstructive jaundice due to a tumor at the head of the pancreas.
  • He was diagnosed with SCLC by transbronchial biopsy from a lung tumor in the left upper lobe.
  • Another 74-year-old male was admitted with jaundice due to a tumor in the porta hepatis.
  • He was also diagnosed with SCLC by a fine-needle aspiration biopsy of a lung tumor in the left lower lobe.
  • Both cases were successfully treated with systemic chemotherapy after endoscopic retrograde biliary drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23754881.001).
  • [ISSN] 1179-142X
  • [Journal-full-title] International medical case reports journal
  • [ISO-abbreviation] Int Med Case Rep J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3658212
  • [Keywords] NOTNLM ; biliary obstruction / jaundice / metastasis / small-cell lung carcinoma
  •  go-up   go-down


91. Fischer L, Friess H, Z'graggen K, Uhl W, Büchler MW: [Operative management in the treatment of pancreatic cancer]. Zentralbl Chir; 2003 May;128(5):390-5
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative management in the treatment of pancreatic cancer].
  • [Transliterated title] Operatives Management bei der Therapie des Pankreaskarzinoms.
  • The carcinoma of the pancreas is one of the 10 leading causes of death in the Western countries.
  • Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure.
  • However, about 80 % of patients with the diagnosis of pancreatic cancer are no more suitable for curative resection at the time of diagnosis because of local tumor infiltration or the presence of distant metastases.
  • In resectable tumors of the pancreas head the standard Whipple dominates still as the surgical method of choice.
  • However, the pylorus preserving Whipple has been established as a surgical alternative to the classical Whipple.
  • Other surgical procedures like extended or regional pancreatic resections, predominantly done by Japanese surgeons seem to fit the concept of radical resection.
  • The prospective European multicenter study ESPAC-1 firstly demonstrated a survival advantage for adjuvant chemotherapy (5-FU and folic acid) but no gain for radiochemotherapy in the treatment of patients with R0 or R1 resected pancreatic cancer in terms of prolongation of mean survival (19.7 months vs. 14.0 months).
  • [MeSH-major] Pancreatic Neoplasms / surgery
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Therapy, Combination. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Hematinics / administration & dosage. Hematinics / therapeutic use. Humans. Multicenter Studies as Topic. Neoplasm Metastasis. Pancreaticoduodenectomy. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12813637.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hematinics; 935E97BOY8 / Folic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Cibeira MT, Lopez-Guillermo A, Colomer D, Ricart MJ, Alcaraz A, Martinez A, Campo E, Montserrat E: Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. Ann Hematol; 2003 Feb;82(2):131-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation.
  • A patient with both a renal and pancreatic transplantation developed a diffuse large B-cell lymphoma, Epstein-Barr virus-related, 14 months after the surgical procedure.
  • Tumor was confined to the transplanted organs: head of the pancreas and hilar lymph node of the transplanted kidney.
  • Chimerism analysis demonstrated the tumor origin from donor lymphoid cells.
  • Immunosuppression was discontinued and chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) was started.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / virology. Pancreas Transplantation / adverse effects
  • [MeSH-minor] Adult. Epstein-Barr Virus Infections / complications. Humans. Kidney Neoplasms / etiology. Kidney Neoplasms / pathology. Kidney Neoplasms / virology. Lymphocytes / pathology. Lymphocytes / virology. Male. Pancreatic Neoplasms / etiology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / virology. Transplantation Chimera


93. Diaconu C, Mateescu D, Bălăceanu A, Marcu M, Jianu V, Stănică A: Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. J Med Life; 2010 Jan-Mar;3(1):96-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.
  • CONTEXT: The complex of symptoms in pancreatic cancer is vague, which often delays presentation and diagnosis.
  • Thrombophlebitis is an unusual presentation of pancreatic cancer, which appears more frequent in the cancer of the body and tail of the pancreas.
  • At the abdomen ultrasound screening, multiple liver masses, relatively well defined, with a hypo-echoic center and a hyper-echoic periphery, were identified.
  • The head of the pancreas was normal, the body and the tail could not be seen very well due to flatulence.
  • After computed tomography, the diagnosis was "Pancreatic tumor with multiple hepatic metastases (stage IV)".
  • At the end of the seventh month of treatment, the patient suffered an irreversible ischemic cardiac event.
  • CONCLUSION: Superficial thrombophlebitis can be the initial manifestation of the pancreatic cancer.
  • Gemcitabine and erlotinib is now a FDA approved regimen for patients with metastatic pancreatic cancer.
  • While the search for the best gemcitabine based backbone for advanced pancreatic cancer continues, studies of anti-angiogenic agents alone or in combination with traditional chemotherapy, should be undertaken, as they may improve overall survival in this group of poor prognosis patients.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Paraneoplastic Syndromes / etiology. Thrombophlebitis / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1425-33 [16012181.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • (PMID = 20302205.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3019029
  •  go-up   go-down


94. Hirashima Y, Kitajima K, Sugi S, Murakami K, Fujioka T, Kumamoto T: [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure]. Gan To Kagaku Ryoho; 2007 Jan;34(1):105-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure].
  • A 56-year-old woman, who had been receiving treatment for chronic renal failure, was admitted to our Department because of a tumor of the pancreas head and multiple liver masses diagnosed by abdominal CT scans.
  • Gastroduodenoscopy revealed a tumor which had invaded the Vater's papilla; the lesion was histopathologically pancreatic adenocarcinoma.
  • Due to the presence of multiple metastases to the liver, we therefore performed general chemotherapy after obtaining the patient's informed consent (IC).
  • After four courses of the treatment, a CT scan revealed both the tumor of the pancreas head and the multiple liver masses to have almost completely disappeared.
  • Our clinical results indicate that CPT-11 may therefore be a strong candidate for first-line chemotherapy for the treatment of pancreatic cancer, especially in patients with renal failure.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Kidney Failure, Chronic / complications. Liver Neoplasms / secondary. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged. Remission Induction


95. Honda K, Fukuhara T, Kojima Y, Tanaka H, Kushihata F, Kobayashi N: [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2089-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
  • Two cases of advanced pancreas cancer were treated with GTX.
  • A 62-year-old man with pancreas head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD.
  • After 3 cycles of GTX, the liver metastases decreased in size, and thereafter tumor markers became lowest after 7 cycles.
  • A 75-year-old man with pancreas head cancer and vascular invasion has been treated with GTX.
  • The tumor reduced in size and tumor markers decreased.
  • GTX is suitable for outpatient chemotherapy with mild adverse effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Invasiveness. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197760.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Yamamoto S, Tanaka Y, Ito T, Aono T, Morimoto Y, Kitagawa T, Kurihara Y: Weekly paclitaxel for a patient with advanced gastric cancer. Gastric Cancer; 2003;6(2):117-21
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel for a patient with advanced gastric cancer.
  • A 56-year-old woman diagnosed with gastric cancer was admitted to our hospital for operation on May 15, 2001.
  • The tumor formed a large mass from the antrum to the head of the pancreas, and cancer cells were detected in the ascitic fluid microscopically.
  • On July 17, a new regimen, of 4-week courses of chemotherapy, with weekly administrations of 65 mg/m2 of paclitaxel, along with premedication for 3 weeks, followed by 1 week of rest, was started.
  • After paclitaxel was started, gastric fiberscopy and computed tomography (CT) scan showed reduction of the tumor.
  • Of special note was the disappearance of a scitic fluid after two courses, rated as a "partial response" (Japanese classification).
  • Neuropathy was slight and no treatment was needed.
  • Now, after 1 year, 11 courses of chemotherapy have been administered at the outpatient clinic.
  • These results suggest weekly administration of paclitaxel to be a promising treatment for advanced gastric cancer with peritoneal dissemination.
  • The therapeutic efficacy should be confirmed by further clinical trials.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Female. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastric Mucosa / radiography. Humans. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884850.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 14
  •  go-up   go-down


97. Liakakos T, Misiakos EP, Tsapralis D, Nikolaou I, Karatzas G, Macheras A: A role for surgery in primary pancreatic B-cell lymphoma: a case report. J Med Case Rep; 2008;2:167
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for surgery in primary pancreatic B-cell lymphoma: a case report.
  • INTRODUCTION: Primary pancreatic lymphoma is a very rare but manageable malignant tumour which may be clinically confused as a pancreatic carcinoma.
  • This case report demonstrates the value of surgical resection in the management of pancreatic lymphoma.
  • Ultrasonography and computed tomography showed a mass at the head of the pancreas which was compressing the bile duct.
  • Histopathologic and immunohistochemical assessment of the pancreatic lesion established the diagnosis of a diffuse, extranodal, high-grade B-cell non-Hodgkin's lymphoma.
  • Several doses of chemotherapy were administered postoperatively and at present the disease remains in remission.
  • CONCLUSION: The favourable outcome for this patient and a thorough review of the literature underline the important role that operative resection may have in the management of at least the early stage of primary pancreatic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):671-5 [10701607.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):898-903 [15198364.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6221-4 [16273656.001]
  • [Cites] Indian J Gastroenterol. 2006 Jan-Feb;25(1):50 [16567907.001]
  • [Cites] BMC Cancer. 2006;6:117 [16674812.001]
  • [Cites] World J Gastroenterol. 2006 Aug 21;12(31):5064-7 [16937508.001]
  • [Cites] Arch Surg. 1990 Aug;125(8):972-6; discussion 976-7 [2378562.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):319-30 [10703858.001]
  • (PMID = 18489739.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396657
  •  go-up   go-down


98. Kamisawa T, Okamoto T: Pitfalls of MRCP in the diagnosis of pancreaticobiliary maljunction. JOP; 2004 Nov;5(6):488-90
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pitfalls of MRCP in the diagnosis of pancreaticobiliary maljunction.
  • CONTEXT: Magnetic resonance cholangiopancreatography (MRCP) is useful for examining the pancreatic duct system in patients with acute pancreatitis instead of using endoscopic retrograde cholangiopancreatography (ERCP), as ERCP-induced pancreatitis represents a serious problem.
  • He had no history of alcohol or drug intake.
  • Abdominal ultrasound demonstrated only a slight swelling of the pancreas, but no abnormal findings for the bile duct or gallbladder.
  • Symptoms and hyperamylasemia improved with supportive therapy.
  • Under the diagnosis of idiopathic acute pancreatitis associated with pancreaticobiliary maljunction without biliary dilatation, prophylactic laparoscopic cholecystectomy was planned.
  • However, ERCP demonstrated a narrow main pancreatic duct and a normal common bile duct without the formation of a common channel.
  • In a supine position, after withdrawal of the scope, the narrow main pancreatic duct at the head of the pancreas overlapped the lower common bile duct, giving the appearance of a long common channel as indicated by MRCP.
  • CONCLUSIONS: In MRCP of cases with a narrow main pancreatic duct, there is a possibility for false-positive indications of pancreaticobiliary maljunction.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance. Common Bile Duct / pathology. Diagnostic Errors. Pancreatic Ducts / pathology. Pancreatitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15536287.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


99. Hashimoto M, Umekita N, Noda K: Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report. World J Gastroenterol; 2008 Jul 7;14(25):4093-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report.
  • Computed tomography (CT) revealed a 10 cm mass in the retroperitoneal space behind the head of the pancreas causing obstruction of the distal bile duct and the PV.
  • A pylorus-preserving pancreaticoduodenectomy combined with a PV resection was performed.
  • Histological examination showed the mass consisting of diffuse sheets of large malignant lymphoid cells.
  • The pathologic diagnosis was diffuse large B-cell type non-Hodgkin lymphoma and the patient was transferred to the Department of Hematology and Oncology for chemotherapy.
  • He received four cycles of combined chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab, and three cycles of intrathecal chemoprophylaxis including methotorexate, cytosine arbinoside and prednisone.
  • The patient is alive with no evidence of the disease for 7 mo after operation and will receive additional courses of chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Bile Ducts / pathology. Chemotherapy, Adjuvant. Humans. Jugular Veins / transplantation. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1188-94 [10811326.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):43-9 [11466812.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2003;33(1):72-4 [12560914.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2323-32 [17406815.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 May 1;71(9):2813-6 [7682150.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):813-9 [17440790.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):503-7 [1323924.001]
  • (PMID = 18609698.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725353
  •  go-up   go-down


100. Song Y, Liu QD, Zhou NX, Zhang WZ, Wang DJ: Diagnosis and management of autoimmune pancreatitis: experience from China. World J Gastroenterol; 2008 Jan 28;14(4):601-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of autoimmune pancreatitis: experience from China.
  • AIM: To determine the clinical, radiographic and pathologic characteristics, diagnostic and treatment modalities in patients with autoimmune pancreatitis (AIP).
  • (1) diagnostic histopathologic features, and abound IgG4-positive plasma cells on pancreatic tissues;.
  • (2) characteristic imaging on computed tomography and pancreatography, together with increased serum IgG, gamma-globulin levels or presence of autoantibodies;.
  • (3) response to steroid therapy.
  • The clinical, radiographic and pathologic characteristics, diagnostic and treatment modalities, and outcome of AIP cases were reviewed.
  • RESULTS: Twenty-five (22 male, 3 female; mean age 54 years, 36-76 years) out of 510 CP patients were diagnosed as AIP, which accounted for 49% (21/43) of CP population undergoing surgical treatment in the same period.
  • The imaging features consisted of pancreatic enlargement, especially in the head of pancreas (18 cases), strictures of main pancreatic duct and intrapancreatic bile duct.
  • Massive lymphocytes and plasma cells infiltration in pancreatic tissues were showed on pathology, as well as parenchymal fibrosis.
  • Twenty-three patients were misdiagnosed as pancreaticobiliary malignancy, and 21 patients underwent exploratory laparotomy, the remaining 4 patients dramatically responded to steroid therapy.
  • No pancreatic cancer occurred during a mean 46-mo follow-up period.
  • CONCLUSION: AIP patients always are subjected to mistaken diagnosis of pancreatic cancer and an unnecessary surgical exploration, due to its similarity in clinical features with pancreatic cancer.
  • The differential diagnosis with high index of suspicion of AIP would improve the diagnostic accuracy for AIP.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Autoimmune Diseases / drug therapy. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / drug therapy. Steroids / therapeutic use
  • [MeSH-minor] Adult. Aged. China. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):6-10 [15773046.001]
  • [Cites] Clin Chem. 2007 Sep;53(9):1700-5 [17712006.001]
  • [Cites] Pancreas. 2005 May;30(4):355-8 [15841047.001]
  • [Cites] Chin J Dig Dis. 2005;6(2):87-92 [15904427.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5577-81 [16222761.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2118-20; discussion 2120 [16344083.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):682-707 [11179244.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):732-8 [11236777.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1264-9 [11984513.001]
  • [Cites] Gut. 2002 Jul;51(1):1-4 [12077078.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):110-20 [12502933.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):129-37; discussion 137-9 [12559194.001]
  • [Cites] Gut. 2003 May;52(5):683-7 [12692053.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):853-8; discussion 858-9 [12796582.001]
  • [Cites] Pancreas. 2003 Jul;27(1):1-13 [12826899.001]
  • [Cites] J Gastroenterol. 2003;38(10):982-4 [14614606.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1557-8 [14628815.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2694-9 [14687819.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1214 [15057766.001]
  • [Cites] Dig Dis Sci. 1995 Jul;40(7):1561-8 [7628283.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1458-68 [9246047.001]
  • [Cites] Am J Dig Dis. 1961 Jul;6:688-98 [13746542.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):552-63 [15517359.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1810-2 [16586561.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2487-96 [16688792.001]
  • [Cites] World J Gastroenterol. 2006 May 14;12(18):2919-22 [16718819.001]
  • [Cites] Pancreas. 2006 Jul;33(1):13-9 [16804407.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1010-6; quiz 934 [16843735.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):613-25 [16932997.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):626-31 [16932998.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6225-8 [17036401.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1537-45 [17122509.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2493-500 [17029619.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):23-8 [16980948.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2670-6 [17182992.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):99-108 [17185087.001]
  • [Cites] Pancreas. 2007 Aug;35(2):156-61 [17632322.001]
  • [Cites] Hepatology. 2007 Aug;46(2):463-71 [17634963.001]
  • [Cites] Gut. 2005 May;54(5):581-3 [15831898.001]
  • (PMID = 18203294.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Steroids
  • [Other-IDs] NLM/ PMC2681153
  •  go-up   go-down






Advertisement